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ABSTRACT
High Frequencies of HIV-1 Recombination and the Evolutionary Potential of a Hybrid
Retrovirus
Terence D. Rhodes

Retroviruses have a great capacity to evolve in order to over come selection pressures in
the environment. Such evolutional power comes from the high mutation rate and the
high viral titers that can ensue during an infection. Mutation generates variation in the
viral genome. In addition, previous reports found that retroviruses recombine at a
relatively high rate. These sources of variation can then be exploited by the population to
ensure the presence of advantageous mutations, which become amplified during virus
propagation. Because the adaptability is based on the evolutionary potential of the virus,
it is essential to study the mechanisms employed in this process. Recombination can
accelerate the generation of multidrug-resistant HIV-1 and therefore presents challenges
to effective antiviral therapy. We determined that HIV-1 recombination rates with
markers 1.0, 1.3, and 1.9 kb apart were 42.4, 50.4, and 47.4% in one round of viral
replication. Because the predicted recombination rate of two unlinked markers is 50%,
we conclude that markers 1 kb apart segregated in a manner similar to two unlinked
markers in one round of retroviral replication. These recombination rates are exceedingly
high even among retroviruses. To explore how efficiently HIV-1 can assort markers
separated by short distances, we developed a flow-cytometry-based system to study
recombination. Using this system, we determined that the recombination rates of markers
separated by 588, 300, 288, and 103 bp in one round of viral replication are 56, 38, 31,
and 12%, respectively, of the theoretical maximum measurable recombination rate.
Statistical analyses revealed that at these intervals, recombination rates and marker
distances have a near-linear relationship that is part of an overall quadratic fit.
Additionally, we examined the effects of target cells and viral accessory proteins on
recombination rate. The results indicated that infection of primary T-cells and the
presence or absence of accessory proteins had no effect on recombination. These results
illustrate the power of recombination in generating viral population variation and predict
the rapid assortment of mutations in the HIV-1 genome in infected individuals.

ii

Table of Contents
Chapter 1

Introduction and Review of Literature……………………………….….1
Overview of dissertation………………………………………………..10
Figure 1: Mature HIV-1 virion…………………………………………12
Figure 2: Genomic organization of HIV-1 provirus……………………13
Figure 3: Replication cycle of a retrovirus……………………………..14
Figure 4: Reverse transcription…………………………………………15
Figure 5: Retroviral recombination models…………………………….16
References………………………………………………………………17

Chapter 2

The evolutionary potential of a hybrid retrovirus....…………………....23
Figures and Legends……………………………………………………33
References………………………………………………………………39

Chapter 3

High rates of human immunodeficiency virus type 1 recombination:
near-random segregation of markers 1 kilobase apart in one round
of viral replication ………………………………………………………46
Tables……………………………………………………………………66
Figures and Figure legends……………………………………………...70
References……………………………………………………………….76

Chapter 4

Genetic recombination of human immodeficiency virus type I in
one round of viral replication: the effects of genetic distances,
target cells, accessory genes, and lack of interference…………….……85
References……………………………………………………………..107
Tables………………………………………………………………….114
Figures and Figure legends…………………………………………….120

Chapter 5

Discussion……………………………………………………………..130
References…………………………………………………………….137

Curriculum Vitae……………………………………………………………………141

iii

List of Tables and Illustrations
Chapter 1

Introduction and Review of Literature…………………………………....….1
Figure 1. Mature HIV-1 virion………………………………………….…12
Figure 2. Genomic organization of HIV-1 provirus………………………13
Figure 3. Replication cycle of a retrovirus………………………………..14
Figure 4. Reverse transcription……………………………………………15
Figure 5. Retroviral recombination models……………………………….16

Chapter 2

The evolutionary potential of a hybrid retrovirus....…………………..……23
Figure 1. Vector and experimental design………………………………..33
Figure 2. RT activity versus time………………………………………...34
Table 1. SNV and MLV production and infection into 293T cells………35
Table 2. TR10 and SNV virus production…………………………….….36
Table 3. TR10 viral propagation in 293T cells…………………………...37
Figure 3. Viral propagation of three different viruses in D17/MS2
cells………………………………………………………………………...38

Chapter 3

High rates of human immunodeficiency virus type 1 recombination:
near-random segregation of markers 1 kilobase apart in one round
of viral replication ………………………………………………………….46
Table 1. Virus titers generated by cell clones containing
TR-HyINproviruses………………………………………………….…….66
Table 2. Virus titers generated by cell clones containing
TR-HyS2NIN and TR-HyINE2B proviruses………………………………67
Table 3. Virus titers generated by cell clones containing
TR-HyN2MIN and TR-HyINE2B proviruses………………………..……68
Table 4. Virus titers generated by cell clones containing
TR-HyN2NIN and TR-HyINN2N proviruses……………………..………69
Figure 1. Viral vectors and protocol used to measure
HIV-1 recombination rates with markers 1 kb apart………………...…….72
Figure 2. Characterization of the proviral structures by
Southern analyses………………………………………………………….73
Figure 3. Southern analyses of the doubly resistant cell
iv

clones from the 1.3-kb marker distance study………………………….…74
Figure 4. Southern analyses of the doubly resistant cell
clones from the 1.9-kb marker distance study……………………………75
Chapter 4

Genetic recombination of human immodeficiency virus type I in
one round of viral replication: the effects of genetic distances,
target cells, accessory genes, and lack of interference……………..……..85
Table 1. Sequence comparison between wild-type and mutant
GFP……………………………………………………………….…….114
Table 2. Recombination between two markers separated by
588 bp…………………………………………………………….……..115
Table 3. Recombination between two markers separated by
300 bp……………………………………………………………….…..116
Table 4. Recombination between two markers separated by
288 bp…………………………………………………………….……..117
Table 5. Recombination between two markers separated by
103 bp……………………………………………………………….…..118
Table 6. Recombination between three markers using ON-H06
and ON-T3 viruses……………………………………………….……..119
Figure 1. Viral vectors and protocol used to measure HIV-1
recombination rates……………………………………………….…….123
Figure 2. Representative flow cytometry analyses of mockinfected cells, producer cells, and cells infected with control
plasmids……………………………………………………………..…..124
Figure 3. Representative flow cytometry analyses of mockinfected and infected target cells……………………………………..…125
Figure 4. Distribution of GFP genotypes and phenotypes in the
progeny generated from double infected cells after one round
of viral replication………………………………………………….…....126
Figure 5. Effects of accessory proteins and target cells on
HIV-1 recombination………………………………………………....…127
Figure 6. Distribution of the GFP+ phenotype in HSA+ and

v

Thy-1+ cells………………………………………………………….…128
Figure 7. Relationship between HIV-1 recombination rate
and marker distance………………………………………………..…..129

vi

CHAPTER 1

INTRODUCTION AND REVIEW OF THE LITERATURE

1

The number of articles dedicated to retrovirology has substantially increased with
the discovery of human immunodeficiency virus type 1 (HIV-1), the major contributing
virus to the AIDS epidemic. Because of the AIDS crisis, much effort has been placed on
the study of retroviruses in order to better understand the mechanisms of replication and
selective pressures these viruses encounter with the hopes that better therapy and an
effective vaccine for this disease will be found. HIV-1 infection continues to be
incredibly difficult to treat. The high mutation rate and the high viral loads that patients
often carry contribute to the enormous genetic variation seen within patients and within
the world population (15, 33, 39-41). Because of this genetic variation, drug resistance
and immune system evasion occurs quickly and complicates therapy (12). Another
aspect is the ability for retroviruses to recombine (29, 48). Retroviral recombination
provides the viral population with a mechanism to readily assort various mutations,
which then can lead to the generation of variants that have increased fitness within the
environment. For example, recombination can assort two different mutations from two
different viruses and generate progeny carrying both of these mutations. Previous to the
work presented in this thesis, it was established that HIV-1 can recombine, as shown in
the literature that recombinant HIV-1 strains are often found in dually infected
individuals (6, 19, 32, 34, 51). In the laboratory, HIV-1 recombination has been observed
to be frequent (11, 25, 26, 31, 36, 42, 52). This apparent high rate of recombination
necessitates a more extensive study into the mechanisms of HIV-1 recombination. Also,
studying mechanisms of retroviral evolution would provide information to combat the
difficult problem of rapid adaptation. These next few pages will outline in detail the
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HIV-1 lifecycle. In addition, current literature on retroviral recombination will be
reviewed, followed by a brief description of the experiments proposed for the completion
of this thesis.
Retroviruses have a unique step in their lifecycle; these viruses carry two copies
of single-stranded full-length viral RNA in virions (3, 17). Upon infection of the host
cell, viral RNA is reverse transcribed into double-stranded DNA, which then is integrated
into the host genome (46). Genes, viral structure, encoded viral proteins, and major steps
in viral replication are described below.
Genes and structures of retroviruses
Retroviruses can be divided into two major classes, simple and complex
retroviruses. HIV-1 is classified as a complex retrovirus. This classification is based on
the presence or absence of accessory proteins in addition to proteins commonly found in
every type of retrovirus. First, gag encodes the structure proteins, which consist of
matrix (MA), capsid (CA), and nucleocapsid (NC), These structure proteins are
transcribed in cells as a polyprotein - Gag. Figure 1 is a schematic representation of a
mature HIV-1 virion. MA provides structure support to the lipid membrane envelope,
CA makes up the outer shell of the condensed core of the virion, and NC is associated
with the genomic RNA. Second are the proteins that perform some of the essential
enzymatic activities for replication. Pol polyprotein consists of two major components
after protease cleavage in all retroviruses; reverse transcriptase (RT) transcribes singlestranded RNA into double-stranded DNA (47) and integrase (IN) allows the integration
of double-stranded viral DNA into the host genome. Protease (PR) cleaves the
polyproteins Pol and Gag into the individual components described above. PR is
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translated as part of Pol in HIV-1 but in some retroviruses it is translated as part of Gag
or as a separate Gag-Pro reading frame. Envelope (Env) is a transmembrane protein
embedded in the outer lipid envelope of the virion. It is responsible for the host range of
the virus, and by interacting with the host cellular receptor, HIV-1 Env mediates virus
entry via direct fusion with the membrane.
The genomic organization of the provirus, the integrated viral genome, of HIV-1
is illustrated in Figure 2. Each end of the proviral structure is composed of long terminal
repeats (LTR). The LTRs can be further subdivided into U3, R, and U5. Immediately
proximal to the LTRs are the primer binding site (PBS) at the 5’ end and the polypurine
tract (PPT) at the 3’ end. These cis-acting elements (R, U5, PBS, and PPT) play crucial
roles during reverse transcription, which is described in detail below. Downstream from
the PBS are sequences important for RNA packaging, gag, pol, and env. In addition, the
positions of HIV-1 accessory proteins, namely vif, vpr, vpu, tat, rev, and nef are indicated
(35).
Retrovirus replication cycle
The replication cycle of a retrovirus (Fig. 3) is discussed in the following
paragraphs from the contact of a virion to a target cell to the production and release of
progeny virus. Since the understanding of reverse transcription is crucial for retroviral
recombination described in this thesis, it will be discussed extensively.
Env interacts with the host cellular receptor, which induces a conformational
change of both proteins that promotes fusion of the virus and cellular membrane. HIV-1
Env interacts with two host proteins for virus entry, namely CD4 and another co-receptor,
most commonly CCR5 or CXCR4. Once fusion has occurred the core of the virion is
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released into the cytoplasm. For most of the retroviruses, reverse transcription starts after
virus entry.
Reverse transcription is the process in which single-stranded RNA is copied into
double-stranded DNA (47) (Fig 4). Reverse transcription start near the 5’ end of viral
RNA using a tRNA as a primer for DNA synthesis. This tRNA primer was packaged
from the previous host into the virion (22, 45). RT then proceeds to transcribe DNA
through the U5 and R region, which this segment of DNA is called minus-strand strong
stop DNA. In addition to the DNA polymerase activity, RT has an RNase H domain that
degrades RNA from a DNA/RNA hybrid. During synthesis, RNase H domain degrades
RNA from the minus-strand strong stop DNA, which leaves the DNA free to anneal
elsewhere. RT then makes the first of two obligatory jumps (or template switches) and
jumps to the 3’ end of the RNA strand; this jump is facilitated by the complimentary
between the R region of the newly synthesized DNA and the 3’ R of the viral RNA (10,
14, 16). Synthesis continues through U3, the protein encoding regions and PBS. RT
makes a sequence specific cut at the PPT and the PPT is used as a primer for plus-strand
DNA synthesis. Plus-strand DNA synthesis proceeds through the U3, R, U5, and the
portion of the tRNA that is complimentary to the PBS; using this complimentarity RT
again jumps (or switches templates) to the complimentary PBS region on the minusstrand DNA. DNA synthesis continues on both strands which yields a double stranded
DNA product (21).
Once reverse transcription is complete, the double-stranded DNA along with IN
enters the nucleus and integrates into the host genome. For some retroviruses, access to
the host genome is thought to be passive and occurs during cell division. After the
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nuclear membrane disassociates the pre-integration complex comes in contact with the
host genome. Other retroviruses have evolved sequences in proteins that bind to viral
DNA to allow viral DNA to pass through the intact nuclear membrane into the nucleus;
these proteins sequences are known as the nuclear localization signal (NLS). This NLS
circumvents the need for cell division and these retroviruses, HIV-1 being among them,
can infect non-dividing cells. IN recognizes specific sequences within twelve to fifteen
nucleotides from either end of the viral DNA called attachment sites (att) (5, 37). These
att sites, which sequences can vary greatly among retroviruses, are imperfect inverted
repeats (37). The att sites are usually specific to the particular retroviral integrase.
However, a CA dinucleotide is found common in all attachment sites. These nucleotides
occupy position three and four proximal of the blunt end viral DNA. For most
retroviruses, sequences closer to the ends of the molecule are assigned greater importance
in efficient integration than others (50). IN must perform two reactions; first, it processes
the 3’ end of the viral DNA by clipping off two nucleotides, and second, IN catalyzes
strand transfer with the cellular DNA to integrate the viral DNA into the host genome. It
has been proposed that the 3’ end processing reaction utilizes water as an intermediate
and the resulting 3’ hydroxyls are used for a nucleophilic attack on the host DNA in the
strand transfer step (4). This attack cleaves the host DNA and allows the provirus to
become integrated. Host enzymes repair gaps in the DNA sequence.
Host cellular machinery drives the transcription of viral mRNA and the
expression of proteins. In the host nucleus, viral mRNA can either remain full length or
become spliced. Env and other accessory proteins are expressed from spliced message.
The full length viral mRNA can be packaged by viral proteins to serve as the genetic

6

material for progeny virus, or the mRNA can be translated for production of Gag and
Gag-Pol polyproteins.
After the syntesis of viral RNA and proteins, viral assembly and packaging of full
length viral mRNA occurs. Gag specifically recognizes and encapsidates the packaging
signal located on the full length viral RNA. The assembled viral proteins and RNA
eventually bud from the cell membrane and are released. After release, the virion
undergoes a maturation step where PR cleaves the polyproteins and forms the mature
condensed core. Infection of another host completes the life cycle.
Retroviral Recombination
Retroviral recombination is the process in which sequences from two different
RNA transcripts are incorporated into the reverse transcribed DNA molecule (29, 48).
Retroviral recombination is facilitated by the packaging of two copies of its viral genome
into virions. If the two co-packaged RNA were different and if RT, during reverse
transription, switches from one co-packaged RNAs to the other, a recombinant DNA
molecule is formed.
Two models have been proposed to explain retroviral recombination, namely the
copy-choice (13) and strand displacement-assimilation models (27) (Fig. 5). The copychoice model is sometimes referred to as minus-strand recombination because it proposes
that the template-switching event takes place during minus-strand DNA synthesis. As
RT proceeds to transcribe along the viral RNA transcript, it is possible that RT can switch
to use the other co-packaged viral RNA transcript as a template and proceed with reverse
transcription. It has been proposed that homology and the dynamic processes of
polymerization and degradation of RNA from the DNA/RNA hybrid play very important
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roles in copy-choice recombination. Experiments examining the required template
switch of strong-stop minus-stand DNA to the 3’ end of the RNA transcript showed that
homology alone was sufficient to facilitate this process (10, 16). In addition, the
examination of a phenomenon called direct-repeat deletion, where an intramolecular
template switch between two similar sequences located on the RNA transcript occurs,
resulting in a deletion of sequences between these two similar repeats, revealed that lack
of homology between the two direct repeats drastically reduced the rate of direct-repeat
deletion (1). Also, mutations of the polymerization domain and RNase H domain of RT
showed that a dynamic relationship exists between the rate of polymerization and the rate
of degradation which effects the rate of template switching (24, 44). The slower the
degradation and/or the faster the polymerization result in a slower rate of template
switching. The opposite is also true; higher rates of direct-repeat deletion were observed
if polymerization slowed down and/or degradation was increased. It is thought that a
situation fostering greater base pairing between the newly transcribed minus-strand DNA
and the homologous region located on the same RNA or co-packaged RNA promotes
template switching (24, 44).
Evidence for the strand displacement-assimilation model was first found by EM
studies (27). In this model, it is assumed that each RNA transcript undergo minus-strand
synthesis and both initiates plus-strand DNA synthesis. Plus-strand synthesis can occur
in a discontinuous and disjointed manner with multiple initiations along the minus-strand
DNA. If one strand were displaced by a leading strand directly upstream from its
position, then it would be free to anneal to a portion of the other minus-strand DNA.
This strand would then become incorporated into the double-stranded DNA product and
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integrated into the host genome. Because this event results in mismatched base pair or
base pairs, the host enzymes must repair the mismatch. If the host enzymes repair the
minus-strand, then a recombinant was generated. There is significance evidence showing
that the copy-choice model is the major contributor in recombination among some simple
retroviruses (2).
Another aspect of the retroviral lifecycle that effects recombination is the rate at
which heterozygotic virions are formed. It has been shown that virus populations that
have the ability to recombine only arise from cells that are infected with more than one
virus (23). A cell containing two proviruses can produce three different types of virus,
namely two different homozygotic virions and one type of heterozygotic virion. If
retroviral proteins package RNA transcripts from the other provirus as efficiently as its
own, than the packaging is random. Random packaging assures that the ratio of total
homozygotic virions to total heterozygotic virions is 1:1 (AA + 2AB + BB). If the
packaging of transcripts from the other provirus is not as efficient, than the formation of
heterozygotic virions occurs at a decreased rate. Since recombination can only be
observed from infection by heterozygotic virions, the lower the frequency of
heterozygote formation, the lower the amount of recombinants will be observed.
Implications of HIV-1 recombination
There has been much learned by studying different aspects of recombination in
simple retroviruses. Many of these findings have already been discussed above, but it is
not known how well these observations correlate with recombination in HIV-1. Evidence
of recombination that has repeatedly been found in infected individuals suggests that
HIV-1 recombination is not a rare event and contributes greatly to variation in te viral
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population. The acquisition of multi-drug resistant HIV-1 mutants has been attributed to
recombination. A greater understanding of this phenomenon must be explored in order to
develop appropriate therapy and vaccine development.
Introduction to Chapter 2, 3, and 4
The end result of the great evolutionary potential of HIV-1 is therapy failure and
immune system evasion. Evolution occurs in response to selective pressures placed on
the viral population. Although both advantageous and deleterious mutants arise during
the generation of viral variation, the advantageous mutants become more fit for the
current environment. In chapter 2, a simple retroviral system that consisted of
propagating a replication-competent chimeric virus was tested to observe evolutional
changes in the viral population. This chimeric virus replicated one hundred fold less than
wild type virus. Examining the changes in the viral population as the defective viral
population evolves into a wild type-like population should show illustrate important
aspects of this process.
Previous experiments in various laboratories have observed HIV-1 appears to
have a high rate of recombination and that there were multiple crossover events occurring
along the genome for those viruses that underwent recombination. However, it has been
difficult from these experiments to determine a recombination rate. A recombination rate
is a measure of the assortment of genetic markers at a certain distance apart in one round
of replication. In chapter 3, experiments determined the recombination rate in HIV-1 at
marker distances of 1.0 kb, 1.3 kb, and 1.9 kb. By using these distances and the same
type of vectors used in the murine leukemia and spleen necrosis viral recombination
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studies, it was possible to not only determine a recombination rate of HIV-1, but also
directly compare that rate to MLV and SNV.
Because HIV-1 has a high rate of recombination, Aim III experiments were
designed to measure the recombination rate at distance less than 1.0 kb. This required the
development of a different system than the one that was utilized in Aim II. The Aim II
system was based on drug resistance markers, where the Aim III system utilized markers
that could be visualized by flow cytometry. Distances of approximately 0.6 kb, 0.3 kb,
and 0.1 kb were measured. Development of the flow cytometry based system also will
allow future recombination experiments to be performed quickly and effectively.
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Figure 1. Mature HIV-1 virion
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Figure 2. Genomic organization of a HIV-1 provirus.
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Figure 3. Replication cycle of a retrovirus.
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Figure 5. Two proposed models to explain the generation of proviral recombinants.
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CHAPTER 2

THE EVOLUTIONARY POTENTIAL OF A HYBRID RETROVIRUS
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Introduction
Retroviruses have a great capacity to evolve in order to over come selection
pressures in the environment. Such evolutional power comes from the high mutation rate
and the high viral titers that can ensue during an infection. Mutation generates variation
in the viral genome. This variation can then be exploited by the population ensure the
presence of advantageous mutations, which become amplified during virus propagation.
Because the adaptability is based on the evolutionary potential of the virus, it is essential
to study the mechanisms employed in this process.
Previous experiments have shown that although SNV and MLV are genetically
distinct retroviruses, SNV can efficiently package and replicate MLV RNA. The reverse
is not true, however. MLV proteins cannot efficiently package and replicate SNV RNA.
This non-reciprocal recognition seems to extend beyond RNA packaging and also include
pol gene products and other cis-acting elements. It has been shown that SNV proteins
can not only package MLV RNA but can also support the replication of MLV vectors at a
frequency similar to that of the SNV-based vectors. This observation indicates that SNV
enzymes can reverse transcribe MLV-based RNA and integrate the DNA efficiently (8,
18). In contrast, MLV pol gene products cannot support SNV vector replication
efficiently. It was found that an SNV Gag/MLV Pol chimera could package both SNVand MLV-based vectors efficiently. However, SNV vector generated titers that were
approximately 100-fold lower than those of the MLV vector (7). This result
demonstrates that MLV pol gene products cannot utilize SNV cis-acting elements
efficiently. The defect could be during reverse transcription when reverse transcriptase
(RT) must interact with certain sequences in the viral genome and/or during integration
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when integrase (IN) needs to recognize the att sites. We hypothesize that if a virus with
incompatible cis- and trans-acting elements is allowed to replicate, through mutations
and selection, better-fit viruses will evolve. By examining the changes that allow the
viruses to become better fit, we can gain an understanding of the elements that are
important in the cis- and trans-acting factors.
Material and Methods
Nomenclature and plasmid construction. The names of all plasmids used in
this study begin with p, but the names of viruses derived from these plasmids do not. The
cloning strategy for constructing pTR10 is as follows. The SNV encapsidation sequence
and a small upstream portion of SNV gag were amplified by PCR from pWH460.
Primers were designed to include an Asp 718 restriction site upstream and two BsmI,
MluI and HindIII sites downstream. This PCR product and pJD214 were cut with the
restriction enzymes Asp718 and HindIII. Vector JD214 is an SNV-based vector that
contains all the cis-acting elements for viral replication. The PCR product was ligated
with pJD214 to generate pTR6. Vector pTR6 and pMP5 were both digested with the
restriction enzyme BsmI. The 5.3 kb fragment from pMP5, which contains most of SNV
gag and all of MLV pol, was ligated into the backbone of pTR6 to pTR7. An olgio
containing a small portion of the 3’ end of amphotropic MLV env, flanked by two ClaI
sites, was inserted into ClaI-digested pTR7 to generate pTR8. Plasmid, pTR8, and
pAMS were digested with ClaI. Because ClaI was methylated at the downstream site,
after the env portion, only a single cut was made in pTR8. Plasmid pAMS is a vector that
encodes replication competent MLV, which includes amphotropic MLV env. ClaI cuts
pAMS within the MLV pol and downstream of the termination codon of amphotropic
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MLV env. This 2.7 kb fragment was ligated into pTR8. The result, pTR10, contains all
the SNV cis-acting elements, SNV gag, MLV pol, and amphotropic MLV env.
RT assay. One milliliter of virus supernatant was collected from tissue culture
and added to 500 µL of polyethylene glycol solution (30% polyethylene glycol, 0.5 M
NaCl). Following incubation in 4ºC overnight, virus was spun at 13,000 RPM for 30 min
on a Heraeus Biofuge centrifuge. Virus was resuspended in 20 µL and subjected to an
RT assay using standard procedures (47).
Cells, transfections and infections and flow cytometry analysis. Cultured cells
were propagated in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal
calf serum for 293T cells and 6% calf serum for D17 cells. Medium was also
supplemented with penicillin (50U/mL) and streptomycin (50U/mL). Cells were
maintained in a 37ºC incubator with 5% CO2.
DNA transfections were performed by the calcium phosphate method (43). Cells
were plated at a density of 1 x 106 cells per 100-mm-diameter dish and transfected 24-hr
later with the appropriate mixture of DNA. The weight ratio of vectors expressing
gag/pol, env, and packaging construct was 5:1:4, respectively. Transfected cells were
placed in a 37ºC incubator with 3% CO2 overnight. Afterwards, the cell culture medium
was changed and cells were placed in a 37ºC incubator with 5% CO2 for another 24 h.
Virus supernatants were harvested and cellular debris was removed by filtering through a
0.45-µm-pore-size filter. Virus was either used immediately or stored at -80ºC prior to
use.
For infection, cells were plated at a density of 1 x 106 cells per 100-mm-diameter
dish or 2 x 105 cells per 60-mm-diameter dish 24 h prior to infection. Cells were infected
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by virus stocks in the presence of Polybrene at a final concentration of 50 µg/mL.
Viruses were removed 4 h later and replaced with fresh media. Cells were washed with
PBS containing 2% fetal calf serum. Acquisition of data was performed on a
FACSCalibur (BD Biosciences).
Results
Experimental design and rationale. The experimental design is illustrated in
Figure 1. Briefly, a replication competent viral vector containing incompatible cis- and
trans-acting elements was transfected into cells. The cells were passed periodically and
at each passage, fresh uninfected cells were added. RT assay was used to monitor the
amount of virus produced from the culture cells. We expect that better-fit viruses would
evolve during viral replication; this would be evident from an increased RT activity in the
cell culture supernatant. After more efficient replicating viruses are detected in the cell
culture system, the sequences of these viruses were amplified from the integrated
provirus by PCR, and the molecular nature of these viruses was determined by sequence
analysis.
Rationale for determining changes in fitness. The fitness of the viral
population was monitored by RT activity. This is an in vitro assay that uses the viral RT
in the virions to reverse transcribe an exogenous RNA template. Radioactive dNTPs are
incorporated in the growing DNA strand during the assay. The amount of radioactivity
measured is directly proportional to the amount of virions in the sample. The RT assay
was used in the following manner. The supernanent was collected at various time points
during the experiment and the amount of virus produced was determined by RT assay.
When RT activity is plotted over time, a characteristic viral propagation profile is created
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(a hypothetical plot is shown in Fig. 2). A wild type virus is expected to spread though
cultured cells quickly and produced large amount of viruses. As a result, the RT activity
from the wild type virus should rise rapidly and remain high during the time course
(dotted line in Fig. 2). In contrast, an unfit virus spreads through culture slowly; the RT
activity should rise slowly and plateau at a lower activity than those from wild type virus.
It may take much longer to see virion production (represented by the dashed line). As the
viral population evolves and becomes more fit (solid line), the replication kinetics will
begin to switch to an intermediate phenotype and eventually bear more similarity to that
of the wild type virus than that of the unfit virus.

Upon identifying a viral population

with altered viral replication kinetics, virus in the supernatant was used to infect fresh
293T cells. PCR was used to amplify proviral sequences from cellular genomic DNA.
These amplified products will then be sequenced. Changes within the viral sequences
will then be identified.
Vector and cell line used to examine viral evolution in cell culture system.
The replication competent vector, pTR10, has all the cis-acting elements needed for SNV
viral replication and SNV gag. However, SNV pol and env are replaced by MLV pol and
amphotropic MLV env. The amphotropic MLV Env allows for the infection of a broad
range of target cells. In addition, it has been shown previously that infectious viral
particles can be generated from SNV Gag/Gag-Pol and MLV amphotropic Env. Human
kidney cells, 293T, are the cells chosen for viral propagation. These cells were chosen
for the following reasons: first, it is easy to achieve high efficiency transfection in 293T
cells. Second, 293T cells are permissive to SNV infection, and third, human cells are
known not to contain MLV-like endogenous retrovirus, which ensures the better-fit
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viruses were generated from adaptation between the cis- and trans-acting elements and
not from recombination events between endogenous viruses and TR10. In previous
experiments, SNV pseudotyped with amphotropic MLV Env efficiently infected 293T
cells (Table 1). Also, transfecting 293T cells with SNV gag/pol constructs produced
significant viral titers (Table 1). These experiments were performed by transfecting
either a plasmid expressing SNV proteins or a plasmid expressing MLV proteins into
293T cells. These two plasmids were transfected with pSR2 (10), a plasmid that confers
hygromycin resistance, and a plasmid encoding amphotropic MLV env. Viral
supernatent harvested from transfected cells was used to infected fresh 293T cells. Based
on these results, these cells should have been ideal for this experiment.
We tested whether TR10 expresses functional viral proteins essential for viral
replication and support the replication of an SNV-based vector. 293T cells were
transfected with either TR10 or pRD136 (a plasmid that expresses SNV wild type
proteins) and a pSR2. Cells that received a plasmid encoding SNV wild type proteins
also were transfected with a plasmid expressing amphotropic MLV Env. Serial dilutions
of the supernatent were used to infect a dog osteosacroma cell line. Cells were put on
hygromycin selection 24 hours later and 2 weeks later resistant colonies were counted to
determine viral titer (Table 2). TR10 does package and replicate an SNV-based vector at
SNV wild type levels, and we concluded that it could be used for the evolution
experiments.
Vector pTR10 was then transiently transfected into 293T cells. After 3 days,
supernatant was collected and cells were mixed with fresh 293T cells at a ration of 1:1.
Three time points were taken and presented in Table 3. As a control, we transfected
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pRD136, which does not produce replication competent virus, to measure RT expression
generated from the initial transfection. Although there was a relative strong burst of RT
activity from TR10 after transfection, TR10 did not have significant replication to
produce RT activity higher than the mock infected sample.
Because we did not observe detectable RT activity for TR10 after the first
passage, a different strategy was employed to test whether virus from pTR10 could
propagate over time. D17 cells were stably transfected with pMS2 (10). The vector
pMS2 is an MLV-based vector that contains two separate portions of green fluorescence
protein (GFP) located in the LTRs. Upon infection with this construct GFP is
reconstituted during reverse transcription. Virus replicating through cells stably
expressing MS2 cells would give an indication of the virus’s replicative capacity due to
the eventual accumulation of GFP positive cells.
Three different viruses were tested in this cell line. Plasmids encoding replication
competent SNV (pCG4), replication competent MLV (pAMS), and pTR10 were
transfected into 293T cells separately and the resulting harvested viruses were then used
separately to infect D17/MS2 cells. GFP expression was monitored periodically for fiftysix days (Fig 3). Replication competent SNV and MLV infected-cells, although with
different kinetics, showed a rise in the percent of GFP-expressing cells, indicating that
virus replication took place. However, cells that were infected with TR10 only had
background levels of GFP-expressing cells, indication that TR10 had a substantial defect
in viral replication.
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Discussion
The experimental system in this report attempted to examine the evolution of a
chimeric simple retrovirus and to investigate the role of sequences and/or protein residues
important for virus replication. These methods have been employed in other systems
with success (9, 28, 49). A defective virus is allowed to replicate over many generations
while monitoring fitness of the viral population. When better-fit virus populations are
detected, strategies to examine the differences in genomic sequences are employed.
Time and virus titer are two dependent factors on evolution experiments. It is not
known how many mutations in the chimeric virus that must be made in order to change
its fitness level. The time it takes to make enough mutations in order to generate a betterfit virus is critical in this experiment. If large pools of infectious progeny virions were
generated from one infected cell then the possibility exist that those advantageous
mutations will occur and produce another round of progeny. However, the probability of
the presence of advantageous mutations becomes meager when only a few progeny
virions are produced per infected cell. A critical mass must be achieved for the described
experiment to work, and the time it takes for TR10 to get to the critical mass is unknown.
Because SNV is an avian virus, it stands to reason that natural host cells might
provide an advantage for virus replication. Performing this experiment in avian cell lines
might generate the critical mass of viral titer to allow evolution to take place. In order for
this experiment to proceed, these cell lines should be evaluated.
There were two conflicting previous reports on the subject of SNV production and
infection in human cells (20, 30). Work described in Koo, et. al. discussed experiments
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in which SNV was able to infect human cell lines, but was not able to produce virus from
the infected cells. They suggested a posttranslation block to productive SNV expression.
However, work from Gautier, R., et. al. showed that SNV can not even infect human
cells. Because a human cell line seemed idea for the evolution experiments, we made
sure that the human cell line, 293T, could produce SNV virus and was permissive to SNV
infection. When SNV was psuedotyped with amphotropic MLV env or GaLVenv,
significant titers were produced upon infection of 293T cells. These same viruses were
produced from transfecting 293T cells with plasmids that express SNV proteins and
packaging constructs. These experiments show that 293T cells do allow production and
are permissive to infection. Although we obtained these results in 2000, recent published
work confirms our conclusions (38). Such information would be valuable to gene
therapies strategies that use retroviral constructs.

32

pTR 10

pT R10

tr ans fection

SN V
LTR

gag

MLV
pol

env

passed
and fresh
cells

continue
passing

LTR
C ell line perm issive to
viral propagation

R T activity

Figure 1. Vector and experimental design

33

PC R and
sequencing

RT activity

wild type

unfit

evolved

TIME

Figure 2. Hypothetical RT activity versus time graph of three different viral populations
with different replication kinetics.
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Average
titer

SNVgag/pol
amphoMLVenv

MLVgag/pol
amphoMLVenv

1.6x103

3.1x103

Table 1. SNV and MLV virus production and infection into 293T cells.
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Average viral titer
(cfm/mL)

TR10 (SNVgag/MLVpol)
4.1 x 103

SNV wt
4.0 x 103

Mock
0

Table 2: TR10 and SNV virus production and infection into 293T cells.
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Day 3
(cpm/min)

Day 6
(cpm/min)

Day 9
(cpm/min)

RD136

247,035

12,906

11,131

TR10

750,550

9,719

9,188

Mock
infected

11,863

10,198

10,304

Table 3. TR10 viral propagation in 293T cells.
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Figure 3. Viral propagation of three different viruses in D17/MS2 cells. d followed by a
number on the x-axis represents the day post infection sample was taken; NC, negative
control.
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Abstract
One of the genetic consequences of packaging two copies of full-length viral
RNA into a single retroviral virion is frequent recombination during reverse transcription.
Many of the currently circulating strains of human immunodeficiency virus type 1 (HIV1) are recombinants. Recombination can also accelerate the generation of multidrugresistant HIV-1 and therefore presents challenges to effective antiviral therapy. In this
report, we determined that HIV-1 recombination rates with markers 1.0, 1.3, and 1.9 kb
apart were 42.4, 50.4, and 47.4% in one round of viral replication. Because the predicted
recombination rate of two unlinked markers is 50%, we conclude that markers 1 kb apart
segregated in a manner similar to two unlinked markers in one round of retroviral
replication. These recombination rates are exceedingly high even among retroviruses.
Recombination rates of markers separated by 1 kb are 4% and 4.7% in one round of
spleen necrosis virus and murine leukemia virus replication, respectively. Therefore,
HIV-1 recombination can be 10-fold higher than that of other retroviruses.
Recombination can only be observed in the proviruses derived from heterozygous virions
that contain two genotypically different RNAs. The high rates of HIV-1 recombination
observed in our studies also indicate that heterozygous virions are formed efficiently
during HIV-1 replication and most HIV-1 virions are capable of undergoing
recombination. Our results demonstrate that recombination is an effective mechanism to
break the genetic linkage between neighboring sequences, thereby reassorting the HIV-1
genome and increasing the diversity in the viral population.
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Introduction
Retroviruses package two copies of RNA into one virion, with each copy
containing the entire genetic information needed for viral replication (16, 29). Although
two copies of RNA are packaged, generally only one provirus is generated from each
infectious event; therefore, retroviruses are considered pseudodiploid and not diploid
(21). Retroviruses have been shown to undergo frequent recombination. One of the
prerequisites for recombination is the formation of heterozygous virions, which contain
two copies of RNA with different genetic information (21, 53). Recombination occurs
during reverse transcription when portions of genetic information from both packaged
RNA copies are used to generate a hybrid DNA copy (7, 52). Genetic recombination
events cannot be identified in the progeny from homozygous virions; these virions
package two identical copies of RNA and, therefore, the recombinants will have the same
genotype as the parental viruses.
Previously, we determined that the recombination rates of spleen necrosis virus
(SNV) and murine leukemia virus (MLV) in one round of viral replication are 4% and
4.7%, respectively, with two markers 1 kb apart (1, 21). In MLV, the recombination
rates increase to 5.0% and 7.4% with markers 1.3 and 1.9 kb apart, respectively (1, 2).
However, when markers are separated by 7.1 kb, the recombination rate is 8.2%, which is
not significantly different from the 7.4% rate observed for markers separated by 1.9 kb
(1).
Recombination can reassort mutations in the viral genome to increase the
diversity of the viral population, which can improve the probability of the survival of the
viral population in a changing environment (7, 52). The selective advantage of having
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frequent recombination events is clearly illustrated in human immunodeficiency virus
type 1 (HIV-1), which causes acquired immunodeficiency syndrome (AIDS). It was
estimated that significant portions of the currently circulating strains of HIV-1 are
recombinants (9, 26, 45, 46). Recombinant strains of HIV-1 have become dominant in
the AIDS epidemic in certain geographical regions; for example, the A/E recombinant
causes many of the HIV-1 infection in Thailand (18, 35). HIV-1 recombination has also
been directly observed in infected patients (15, 34, 47, 56).
Much research effort has been devoted to understanding HIV-1 recombination.
Recombination has been observed during reverse transcription in vitro using purified
nucleic acids and proteins (3, 12-14, 38, 39). Frequent HIV-1 recombination events have
also been observed in cell culture systems (6, 22, 30, 42, 50). More recently, the
frequency of HIV-1 recombination was estimated by studying recombination between
two similar strains of HIV-1 and mapping the crossovers by using a heteroduplextracking assay (23, 57). These studies revealed that within limited cycles of replication,
many HIV-1 genomes contained more than one recombination event; an average of 2-3
crossovers per genome was estimated. These studies are highly informative; however,
direct comparisons among the HIV-1, SNV, and MLV recombination rates are
complicated by the different strategies used to calculate the recombination frequencies.
In this report, we measured HIV-1 recombination rates in one round of viral
replication. We found that HIV-1 recombines at an exceeding high frequency even when
compared with other retroviruses such as MLV and SNV. These comparisons were made
possible by using the same target sequences measured in the MLV recombination studies.

49

Materials and Methods
Nomenclature and plasmid construction. The names of all plasmids used in
this study begin with p but the names of the viruses derived from these plasmids do not;
for example, pTR-HyIN refers to a plasmid and TR-HyIN refers to the virus or provirus
derived from this plasmid. Plasmids were constructed using standard molecular cloning
techniques (48). Plasmid pTR-HyIN was constructed from pJS30 (1) and pKDHIV(PIN), which was a generous gift from Dr. Vinay K. Pathak and a derivative of
pHR’-CMVLacZ (37). Plasmids pKD-HIV(PIN) and pJS30 were digested with BamHI
and BsrGI, respectively, treated with the Klenow fragment of Escherichia coli DNA
polymerase I (Klenow) to fill in the 3’ ends of DNA fragments, and then digested with
BclI. The 1.8-kb DNA fragment derived from pJS30 containing hygromycin
phosphotransferase B gene (hygro)(19) and internal ribosomal entry site (IRES) from
encephalomyocarditis virus (EMCV) was ligated to the backbone from pKD-HIV(PIN) to
generate pTR-HyIN, which contains hygro and the neomycin phosphotransferase gene
(neo) (24). To generate pTR-HyS2NIN, pTR-HyIN was digested with SacII, treated with
T4 DNA polymerase to remove the protruding 3’ termini, and self-ligated. This
treatment generated an inactivating frameshift mutation in hygro, destroyed the SacII site
and generated an NgoMIV site. To generate pTR-HyN2MIN, pTR-HyIN was partially
digested with NdeI, then a linker (5’-TATGACGCGTCA-3’) was inserted; these
treatments generated a 10-bp addition to the sequence, which resulted in an inactivating
frameshift mutation in hygro and an additional MluI site. To generate pTR-HyINE2B, a
0.9-kb MscI-to-BamHI region in pTR-HyIN was replaced by its counterpart from pJA321kb (1); the resulting plasmid contained the same structure as pTR-HyIN except for a 4-
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bp inactivating insertion in neo that destroyed an EheI site and added a BssHII site.
Plasmid pTR-HyIN was partially digested with NcoI, treated with Klenow enzyme, and
ligated to generate pTR-HyN2NIN and pTR-HyINN2N, which contained a 4-bp insertion
that inactivated hygro and neo, respectively.
Cells, transfections, and infections. Cultured cells were propagated in
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal calf serum, penicillin
(50 U/ml), and streptomycin (50 U/ml). Cells were maintained in a 37ºC incubator with
5% CO2.
DNA transfections were performed by the calcium phosphate method (48) using
an MBS Mammalian Transfection Kit (Strategene). Cells were plated at a density of 4 ×
106 per 100-mm-diameter dish and transfected 18 h later with a mixture of DNA. After
incubating for 4 h at a 37ºC incubator with 3% CO2, the DNA mixture was removed,
fresh medium was added to the cells, and the cells were transferred to a 37ºC incubator
with 5% CO2. Viral supernatants were harvested 24 h later; cellular debris was removed
by filtering the supernatants through a 0.45-µm filter. Viral supernatants were either used
immediately or stored at -80ºC prior to infection. Helper constructs pCMV∆R8.2 (36)
together with pSV-A-MLV-env (31) or pHCMV-G (54) were transfected into cells to
generate viruses. Plasmid pCMV∆R8.2 expresses all HIV-1 viral proteins needed for
infection except Env. Plasmid pSV-A-MLV-env or pHCMV-G expresses amphotropic
MLV Env or vesicular stomatitis virus G protein (VSV-G), respectively. DNA mixtures
used for transfection were either at a 5 : 1 : 4 (pCMV∆R8.2 : pSV-A-MLV-env : vector)
or 2 : 1 (pCMV∆R8.2 : pHCMV-G) ratio.
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For the infection procedure, target cells were plated at a density of 1 × 105 per 60mm-diamter dish 24 h prior to infection. Serial dilutions were generated from each viral
stock and used for infection in the presence of Polybrene at a final concentration of 50
µg/ml. Viruses were removed 4 h later and drug selections were carried out 24 h
postinfection. Selection with hygromycin, G418, or hygromycin plus G418 were
performed at 170, 609, or 170 plus 473 µg/ml, respectively.
Southern hybridization analyses. Genomic DNAs from infected cells were
purified using the QIAamp DNA Blood Mini Kit (Qiagen) or AquaPure Genomic DNA
Isolation Kit (BioRad). Southern hybridization was performed by standard procedures
(48). A 1.0-kb HindIII-to-NgoMIV DNA fragment derived from pWH390 (1) containing
the 3’ portion of the IRES, and the 5’ 0.6-kb portion of neo was used to generate a 32Plabeled probe by random priming (17) (Random Primed DNA Labeling Kit, Roche).
Southern hybridization results were obtained by autoradiography or PhosphorImager
analyses.

RESULTS
Strategy used to measure HIV-1 recombination rates. The following
constructs and strategy were used to measure the HIV-1 recombination rates. We
constructed an HIV-1-based vector (pTR-HyIN) that expresses hygro and neo, which
confer resistance to hygromycin and G418, respectively. In this vector, hygro expression
is directed by an internal cytomegalovirus promoter, whereas neo expression is directed
by an EMCV IRES (Fig. 1). Plasmid pTR-HyIN also contains all the cis-acting elements
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essential for viral genome replication; however, it does not express HIV-1-encoded viral
proteins.
Two vectors were derived from pTR-HyIN, each containing an inactivating
mutation in one of the drug-resistance genes. Vector pTR-HyS2NIN contains an
inactivating frameshift mutation in hygro that destroys a SacII site and generates an
NgoMIV site, whereas pTR-HyINE2B contains an inactivating frameshift mutation in
neo that destroys an EheI site and generates a BssHII site (Fig. 1). The distance between
the SacII site in hygro and the EheI site in neo is 1 kb. Because these two vectors each
contain only one functional drug-resistance gene, a provirus derived from pTR-HyS2NIN
or pTR-HyINE2B can only confer resistance to one drug selection. However, if
recombination occurs within the 1-kb distance separating the mutations, it could generate
a provirus containing two functional drug-resistance genes conferring resistance to
double drug selection. By measuring the frequency at which recombinants with two
functional genes are generated, we can calculate the recombination rate between markers
1 kb apart.
The protocol used to measure the HIV-1 recombination rate is illustrated in Fig.
1B. TR-HyS2NIN- or TR-HyINE2B-containing virions were generated separately by
transfecting 293T cells with vector plasmid, pCMV∆R8.2, and pSV-a-MLV-env. Helper
construct pCMV∆R8.2 expresses most HIV-1-encoded proteins except Env, whereas
pSV-A-MLV-env expresses the amphotropic MLV Env, which can functionally replace
HIV-1 Env to generate infectious pseudotyped HIV-1 virions. These viruses were used
to infect 293 cells simultaneously, and the resulting hygromycin-plus-G418 double
resistant cell clones were selected and characterized by Southern analyses. Only cell
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clones containing one copy of each provirus with intact structures were selected and used
for further experiments.
To measure the recombination rate, these characterized cell clones were
transfected with helper constructs pCMV∆R8.2 and pHCMV-G, which expresses VSVG. VSV-G can be used to generate infectious pseudotyped HIV-1 virions. Twenty-four
hours after transfection, viruses were harvested and serial dilutions were generated.
These viral stocks were used to infect 293 target cells in triplicates; these cells were then
selected with hygromycin, G418, or hygromycin plus G418. The numbers of drugresistant cell colonies were determined and viral titers were calculated. Hygromycinplus-G418-resistant cell clones were isolated and the molecular nature of the proviruses
was characterized. These data were used to calculate the frequency at which
recombinants with two functional drug-resistance genes were generated. This frequency
was then used to calculate the recombination rate.
Comparisons of TR-HyIN-derived viral titers resulting from different drug
selections. The strategy described above relied on viral titers generated from different
drug selections to calculate how frequently recombinants with two functional genes were
generated. Therefore, it was important to first define the relative viral titers from
different drug selections. Using a protocol similar to that described above, we generated
cell clones containing a single copy of TR-HyIN provirus. Viruses were generated from
these cells and used to infect 293 target cells; hygromycin, G418, or hygromycin-plusG418 viral titers were determined. A summary of viral titers generated from five
different cell clones is shown in Table 1. In each of the five cell clones, viral titers
generated by the three selection regimens were similar. Therefore, viral titers generated
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from single and double drug selections reflect the number of infection events and can be
used to calculate recombination rates.
Measuring HIV-1 recombination rates with two markers 1 kb apart. Using
the aforementioned protocol, we generated cell clones containing a copy of each TRHyS2NIN and pTR-HyINE2B provirus with intact structures. These characterized cell
clones were transfected with helper constructs pCMV∆R8.2 and pHCMV-G to generate
viruses; the resulting viral titers from five cell clones are summarized in Table 2. In
general, hygromycin and G418 viral titers within each cell clone were similar, indicating
that the two parental proviruses were expressed at similar levels; in addition, the
hygromycin-plus-G418 viral titers were approximately 20% of the single drug-resistant
viral titers. Each of the parental viruses can only confer single drug resistance; a doubly
resistant cell can be generated by the presence of both parental viruses or by the presence
of a recombinant virus with two functional drug-resistance genes. To characterize the
molecular nature of the proviruses in the doubly resistant cells, we isolated 11
hygromycin-plus-G418-resistant target cell clones and performed Southern analyses (Fig.
2). The two parental viruses are identical in sequence except for the two inactivating
mutations, which convert a SacII site in hygro to an NgoMIV site and an EheI site in neo
to a BssHII site. Therefore, the nature of the proviruses can be distinguished by Southern
analyses. A representative Southern analysis is shown in Fig. 2B. DNA samples were
digested with NgoMIV plus EheI and hybridized with a probe generated from a DNA
fragment containing the 3’ half of IRES and most of neo. A provirus derived from one of
the parental viruses should generate either a 1-kb band plus a 0.5-kb band (TRHyS2NIN) or a 2.3-kb band (TR-HyINE2B), whereas a recombinant provirus with two
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functional genes should generate a 1.8-kb band plus a 0.5-kb band. Southern analyses of
DNA samples from two types of cells are shown: virus-producing cells, and doubly
resistant target cells infected with virus generated from the producer cells. Lanes labeled
1.0B2, 1.0C3, and 1.0C4 contained DNA isolated from virus producer cell clones doubly
infected with the two parental viruses. In each of these lanes, three bands were detected,
corresponding to the expected 2.3, 1.0, and 0.5 kb fragments. In contrast, a 1.8-kb band
and a 0.5-kb band were observed in DNA samples isolated from resistant target cell
clones (lanes labeled B2B1, B2B2, B2C1, C3A1, and C4B1). All of the 11 target cell
clones contained recombinant proviruses (Fig. 2 and data not shown). These results
indicate that most of the hygromycin-plus-G418-resistant viral titers were generated from
infection of recombinant proviruses rather than double infection of the two parent
viruses. Therefore, the doubly resistant viral titers reflect the amount of recombinants
containing two functional drug resistance genes.
Two types of recombinants can be generated in this system: recombinants with
two functional drug resistance genes and recombinants with two inactivated genes.
Because the double drug selection protocol specifically detected recombinants with the
two functional drug-resistance genes, only half of the recombination events were
measured. To calculate the recombination rate, the hygromycin-plus-G418 viral titers
were divided by the lower of the two single drug selection titers, and then multiplied by
two. The average recombination rate from the five clones is 42.4 ± 1.8% [standard error
(SE), Table 2].
Theoretical recombination rate of unlinked markers in this system. We
performed the following calculation to estimate the recombination rate of two unlinked
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markers (Fig. 3). Assuming that in the virus-producing cells, RNA expression of the two
proviruses is equal, and the formation of homozygous and heterozygous virions is
random, then 50% of the virions should be heterozygous, 25% of the virions should be
homozygous containing two copies of TR-HyS2NIN RNA, and 25% of the virions
should be homozygous containing two copies of TR-HyINE2B RNA. Homozygous
virions generate progeny proviruses with the same phenotypes as their parents. In
contrast, heterozygous virions can generate four different types of progeny proviruses:
the TR-HyS2NIN phenotype, the TR-HyINE2B phenotype, the recombinant phenotype
with two functional drug-resistance genes, and the recombinant phenotype with two
inactivated genes. If the mutations in hygro and neo are unlinked, then random
segregation is predicted, which infers that the four different phenotypes of progeny
proviruses should be generated at the same frequencies. Therefore, of the 50%
heterozygous virions, 12.5% of each phenotype of progeny is generated. Totaling all of
the progeny generated by both homozygous and heterozygous virions, 50% of the
proviruses should confer resistance to a single drug selection (25% from the homozygous
virions, 12.5% from the parental phenotype generated from heterozygous virions, and
12.5% from the double drug-resistance phenotype), whereas 12.5% of the proviruses
should confer resistance to double drug selection. Therefore, the recombination rate
should be 50% [(12.5% / 50%) × 2].
HIV-1 recombination rate does not increase significantly when markers are
1.3 or 1.9 kb part. The rate that we measured with two markers 1 kb apart is 42.4%,
which approaches the rate at which two markers reassort randomly. To investigate
whether the HIV-1 recombination rate can increase further, we measured the
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recombination rates when two markers are 1.3 or 1.9 kb apart. These two distances were
chosen because using the same target sequences we have previously measured the MLV
recombination rates when markers were 1.3 or 1.9 kb apart (1, 2); additionally, the 1.9-kb
recombination rate is significantly higher than the 1.0-kb recombination rate (1).
Three vectors were derived from pTR-HyIN; the structures of their proviruses are
shown in Fig. 3A and 5A. Vector pTR-HyN2MIN contains an inactivating frameshift
mutation in hygro that introduced an MluI site in an NdeI site; when paired with the
previously described pTR-HyINE2B, the recombination rate with markers 1.3 kb apart
can be determined (Fig. 3A). Vector pTR-HyN2NIN contains an inactivating mutation in
hygro that changed an NcoI site to an NsiI site, and pTR-HyINN2N contains an
inactivating mutation in neo that changed an NcoI site to an NsiI site (Fig. 4A); the
distance between the NcoI site of hygro and the NcoI site of neo is 1.9 kb.
Using a protocol identical to that used to measure the recombination rate between
markers 1.0 kb apart, we generated and characterized cell clones containing one copy
each of TRHyN2MIN and TR-HyINE2B. Helper constructs were used to transfect these
cell clones, viruses were harvested, target cells were infected, and viral titers were
determined. Viral titers generated from five different cell clones are summarized in
Table 3. Because all the inactivating mutations are accompanied by restriction enzyme
site alterations, the structures of the proviruses with a parental or recombinant genotype
can be distinguished by Southern analyses. To characterize the molecular nature of
proviruses in the hygromycin-plus-G418 resistant cells, we isolated and analyzed DNA
from doubly resistant target cell clones. As illustrated in Fig. 3A, after digestion with
MluI, EheI, and XhoI and hybridization with probes generated from the aforementioned
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DNA fragment, proviruses with parental genotypes are expected to have either a 1.3-kb
band plus a 0.8-kb band, or a 2.7-kb band, whereas recombinant proviruses with two
functional genes are expected to generate a 1.8-kb and a 0.8-kb band. A representative
Southern blot is shown in Fig. 3B; the two virus-producing cell clones (1.3A4 and 1.3C2)
contained the two parental proviruses, whereas the three doubly resistant target cell
clones (A4A4, C2C3, and C2C5) contained recombinant proviruses with two functional
genes. All of the eight doubly resistant target cell clones that were analyzed contained
recombinant proviruses with two functional drug-resistance genes (Fig. 3 and data not
shown). These data indicate that the hygromycin-plus-G418-resistant viral titers reflect
the numbers of recombinant proviruses containing two functional drug-resistance genes.
Therefore, the average recombination rate of two markers 1.3 kb apart is 50.4 ± 3.7 %
(SE, Table 3).
Using the same protocol, we established and characterized cell clones containing
a copy each of TR-HyN2NIN and TR-HyINN2N proviruses. Viral titers were measured
from seven of these cell clones; these data are summarized in Table 4. Similar to data
generated from cell clones containing proviruses with markers 1.0 and 1.3 kb apart,
within each cell clone, the two single-selection titers are generally comparable whereas
the double drug selection titers are approximately 20% - 25% of the single-selection
titers. Doubly resistant target cell clones were isolated, and the proviral structures were
analyzed. As shown in Fig. 4A, when digested with NcoI and XhoI and hybridized with
probes, the two parental proviruses are expected to generate a 2.7-kb band and a 2.3-kb
band, whereas the recombinants with two functional genes are expected to generate a 1.9kb band. A representative Southern blot is shown in Fig. 4B; the two virus-producing
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cell clones (1.9B3 and 1.9G2) contained the two parental viruses, and the four doubly
resistant target cell clones contained the recombinant proviruses (B3A1, G2A1, G2A2,
and G2B1). We examined nine double drug resistant target cell clones and all of them
contained recombinant proviruses with two functional drug-resistance genes (Fig. 4 and
data not shown). Therefore, the average recombination rate with markers 1.9 kb apart is
47.4 ± 2.2 % (SE, Table 4). Therefore, HIV-1 recombination rate does not increase
significantly when the marker distance is increased from 1.0 kb to 1.3 or 1.9 kb apart.
Furthermore, all three rates remain similar to the 50% predicted rate on unlinked markers.
The experimental protocols used in these experiments mainly measured events
that occurred during one round of HIV-1 replication. Viruses were harvested from cells
24 h after transfection; in order for more than one round of viral replication to occur, viral
proteins have to be expressed from the transfected helper plasmids, and virions have to be
generated, infect new target cells, complete the viral replication cycle, express the
proviral genome, and form new viruses within 24 h. We estimate that only a very small
percentage of the events measured in the system will be derived from more than one
round of replication and these infrequent events should not affect the recombination rate
that we measured. To test this, we generated two cell pools, one containing TRHyN2NIN proviruses and one containing TR-HyINN2N proviruses. Equal numbers of
cells from these two pools were mixed together, and transfected with helper constructs,
then viruses were harvested and used to infect target cells by the same protocol described
above. Because the two cell pools each contained only one parental virus, only
homozygous virions should be produced; thus, recombinant proviruses with two
functional drug-resistance genes should not be generated in one round of viral replication.
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However, cells containing both parental proviruses could be generated after the first
round of viral infection, and recombinant proviruses could be generated at later
replication cycles. We observed that the hygromycin-plus-G418 double resistant viral
titer was less than 2% of the single-selection viral titers, which is in sharp contrast with
the previous experiments using coinfected cell clones. This experiment demonstrated
that the majority of the events measured in this system occurred in one round of viral
replication.

Discussion
High rates of HIV-1 recombination and their implications. In this report, we
described a series of experiments measuring HIV-1 recombination rates. We found that
the recombination rate in one round of viral replication is 42.4% with markers 1 kb apart,
which predicts that two markers separated by 1 kb can reassort at a frequency similar to
that of unlinked markers. This observation indicates that recombination is an incredibly
powerful tool to break the linkage between neighboring sequences in the viral genome,
thereby generating diversity in the viral population and increasing the evolutionary
capacity of HIV-1. This heightened ability to generate diversity also presents more
challenges in the development of effective anti-HIV-1 treatments and vaccines. Although
many anti-HIV-1 drugs have been developed in the past decades, resistance-conferring
mutations in the HIV-1 genome have been observed for every FDA-approved drug. For
example, mutation L10I in protease confers resistance to indinavir and lopinavir (8, 28),
and mutation T215Y in reverse transcriptase confers resistance to AZT (27, 32). These
two mutations are separated by approximately 1 kb, and should segregate randomly if
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recombination occurs between a virus with L10I and a virus with T215Y. Therefore, the
high rates of recombination can accelerate the generation of multi-drug-resistant HIV-1
strains. In addition, high recombination rates are also important to the generation of
novel strains of HIV-1. HIV-1 isolates are classified into group M, N, and O based on
sequence identity; the vast majority of the isolates belong to group M, which is further
divided into different subtypes (44). Recombination can occur between closely related
strains (15, 34, 47, 56), between isolates from different subtypes (4, 5, 10, 33, 43, 49, 55),
or even between different HIV-1 groups (41, 51). Currently, many of the circulating
strains of HIV-1 are intersubtype recombinants (9, 26, 45, 46). The high rates of
recombination indicate that the mixing of the viral genomes from different strains can
occur much faster than previously anticipated, and novel HIV-1 variants can also be
generated at an accelerated pace.
Efficient formation of heterozygous HIV-1 virions. Previously, we
demonstrated that the formation of the heterozygous virions is critical to SNV and MLV
recombination [(21), Anderson and Hu, unpublished data]. Here, we also show that high
rates of recombination occurred when viruses were harvested from cell clones containing
both parental viruses (thus allowing the formation of heterozygous viruses) but not from
coinfection of two stocks of homozygous viruses. Therefore, similar to simple
retroviruses, the high frequency of HIV-1 recombination also requires heterozygous
virion formation.
We calculated the hypothetical recombination rate of unlinked markers with the
assumptions that RNA expressed from the two parental viruses would be equal and the
formation of homozygous and heterozygous virions would be random. The calculated
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hypothetical rate (50%) is similar to our measured rate (42.4 to 50.4%). Our titer data
indicate that within each cell clone, the two parental viruses were expressed at similar
levels (Tables 2-4). These results validate the assumption regarding RNA expression.
The observed high recombination rates in these experiments allow us to conclude that
heterozygous virions must be formed efficiently during HIV-1 replication.
Comparison of SNV, MLV, and HIV-1 recombination. The HIV-1
recombination rates described in this report are approximately 6- to 9-fold higher than the
MLV recombination rates (1-kb distance: 4.7% versus 42.4%, 1.9-kb: 7.4% versus
47.4%). Because the same target sequences were used in the measurement of HIV-1 and
MLV recombination rates, the large difference in recombination rates most likely reflects
the difference between MLV and HIV-1 replication. Previously, we observed that in
SNV and MLV, intramolecular template switching occurred far more frequently than
intermolecular template switching (1, 11, 20, 21, 25). We hypothesized that although
most viruses are capable of undergoing intramolecular template switching, only a
subpopulation of the virions are capable of undergoing intermolecular template switching
(recombination) (20). We provided two possible explanations for the limited
recombination subpopulation: nonrandom copackaging of viral RNA (inefficient
heterodimer formation), or altered structures of reverse transcription complex which
hampered the access of both RNA copies to be used as the template during reverse
transcription (20). Currently, we do not know the mechanisms that limit the
intermolecular template-switching events in MLV and SNV. However, HIV-1 does not
appear to have the same constraints, because we were able to measure a 42.4-50.4%
recombination rate in HIV-1, similar to the 50% hypothetical recombination rate of
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unlinked markers. Therefore we can also conclude that a major portion of HIV-1 viruses
are capable of undergoing intermolecular template switching (recombination) events.
As we were completing this manuscript, a report was recently published
concluding that HIV-1 recombines more frequently than MLV (40). There are several
differences in the systems used and the conclusions of these two studies. In our study,
viruses were harvested from producer cell clones that were characterized to contain a
copy of each parental provirus, whereas in the other study viruses were generated by
transiently cotransfecting two vectors and helpers. Cell clones produced viruses have
several advantages. First, viral RNAs were generated from proviruses, and we measured
any bias in the transport and sorting of RNA expressed from proviruses integrated at
different locations of the host chromosomes. Second, the homogeneity of the
characterized cell clones allows assessment of the expression levels of the two
proviruses, which can be used to estimate the efficiency of heterologous virions
formation. Such estimation cannot be easily obtained using viruses generated from a
transfected pool because the heterogeneity of such pools creates uncertainty about the
numbers of doubly transfected cells and the expression levels of the vectors in each cell.
Third, DNA recombination during transfection is not a complicating factor in our system.
In addition, our system allows the simultaneous scoring of the two parents and the
recombinants. In both systems, recombination is scored by the simultaneous presence of
the two parental phenotypes, which can be complicated by double infection of the two
parental viruses. We have characterized target cell clones to ensure that our
measurements reflected the recombination events.
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There are differences in our conclusions as well. We have measured HIV-1
recombination rates at three marker distances; we have observed that markers 1 kb apart
can segregate in a manner similar to unlinked markers in one round of retroviral
replication, which has strong implications for HIV-1 evolution and the development of
antiviral treatments and vaccines. In addition, we concluded that heterozygous virions
are formed efficiently in HIV-1, and most of the HIV-1 virions are capable of carrying
out recombination events.
The results from our study add to a growing body of evidence that HIV-1
recombination is an important factor in generating diversity in the viral population.
Many questions about HIV-1 recombination remain to be answered, such as the
mechanisms of recombination and the factors that affect recombination. However, our
current understanding indicates that the rapid redistribution of mutations in the viral
genomes must be taken into account when designing new treatment regimens and
developing effective vaccines.
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TABLE 1. Virus titers generated by cell clones containing TR-HyIN proviruses
Titers (102 CFU/ml)

Clone
Hygromycin

G418

Hygromycin + G418

HN A1

1.4

1.8

1.2

HN C1

2.2

2.8

2.4

HN C3

4.1

5.0

3.6

HN E2

3.7

5.2

2.8

HN E4

0.3

0.7

0.4
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TABLE 2. Virus titers generated by cell clones containing TR-HyS2NIN and TRHyINE2B proviruses
Titers (102 CFU/ml)

Clone

Recombination rate (%)

Hygromycin

G418

Hygromycin + G418

1.0B2

0.9

1.1

0.2

44.4

1.0C2

1.4

1.8

0.3

42.8

1.0C3

1.4

2.5

0.3

42.8

1.0C4

11.4

11.2

2.6

46.4

1.0D1

7.7

6.7

1.2

35.8

Avg ± SE

42.4 ± 1.8
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TABLE 3. Virus titers generated by cell clones containing TR-HyN2MIN and TRHyINE2B proviruses
Titers (102 CFU/ml)

Clone

Recombination rate (%)

Hygromycin

G418

Hygromycin + G418

1.3A1

9.5

8.3

2.2

53.0

1.3A4

13.7

13.6

3.0

44.1

1.3C2

9.1

10.3

2.2

48.4

1.3E3

4.4

8.5

1.4

63.6

1.3F4

9.7

8.8

1.9

43.1

Avg ± SE

50.4 ± 3.7
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TABLE 4. Virus titers generated by cell clones containing TR-HyN2NIN and TRHyINN2N proviruses
Titers (102 CFU/ml)

Clone

Recombination rate (%)

Hygromycin

G418

Hygromycin + G418

1.9B1

2.5

3.1

0.51

40.8

1.9B3

3.9

4.1

1.1

56.4

1.9B4

7.5

8.2

2.0

53.3

1.9C2

9.5

6.7

1.6

47.8

1.9D1

10.7

11.5

2.4

44.9

1.9G2

11.3

9.3

1.9

40.9

1.9I2

11.7

15.2

2.8

47.9

Avg ± SE

47.4 ± 2.2

69

FIGURE LEGENDS
FIG. 1. Viral vectors and protocol used to measure HIV-1 recombination rates
with markers 1 kb apart. (A) General structures of the vectors. pro, CMV promoter;
hygro, hygromycin phosphotransferase B gene; IR, internal ribosomal entry site; neo,
neomycin phosphotransferase gene; asterisk, inactivating frameshift mutation. N,
NgoMIV; B, BssHII; S and E with slash, destroyed SacII and EheI sites, respectively.
(B) Protocol used to measure recombination rates.

FIG. 2. Characterization of the proviral structures by Southern analyses. (A)
Partial restriction enzyme maps of parental and recombinant proviruses. A 1.0-kb DNA
fragment (probe) was used for the random-priming reaction to generate a probe for
Southern hybridization analysis. E, EheI. (B) A representative Southern analysis of
virus-producing cells and the doubly resistant cell clones. 1.0B2, 1.0C3, and 1.0C4 were
doubly infected cell clones used to produce virus to measure recombination rates. B2B1,
B2B2, and B2C1 were hygromycin-plus-G418-resistant target cell clones infected by
viruses harvested from 1.0B2; C3A1 and C4B1 were doubly resistant target cell clones
infected by viruses harvested from 1.0C3 and 1.0C4, respectively. Molecular size
markers are indicated on the right of the Southern blot. All abbreviations are the same as
in Fig. 1.

FIG. 3. Southern analyses of the doubly resistant cell clones from the 1.3-kb
marker distance study. (A) Partial restriction enzyme maps of proviruses. M, MluI; X,
XhoI. (B) A representative Southern analysis of virus-producing cells and the doubly
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resistant target cell clones. 1.3A4 and 1.3C2 were doubly infected cell clones used to
produce virus to measure recombination rates. A4A4, C2C3, and C2C5 were
hygromycin-plus-G418-resistant target cell clones infected by viruses harvested from
1.3A4 and 1.3C2. Molecular size markers are indicated on the left of the Southern blot.
Other abbreviations are the same as Fig. 1 and 2.
FIG. 4. Southern analyses of the doubly resistant cell clones from the 1.9-kb
marker distance study. (A) Partial restriction enzyme maps of proviruses. Ns, NsiI; Nc,
NcoI; Nc with slash, destroyed NcoI. (B) A representative Southern analysis of virusproducing cells and the doubly resistant target cell clones. 1.9B3 and 1.9G2 were doubly
infected cell clones used to produce virus to measure recombination rates. B3A1, G2A1,
G2A2, and G2B1 were hygromycin-plus-G418-resistant cell clones infected by viruses
harvested from 1.9B3 and 1.9G2. Molecular size markers are indicated on the left of the
Southern blot. All abbreviations are the same as in Fig. 1, 2, and 4.
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Fig. 1.
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Fig. 2.
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Fig. 3.
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Fig. 4.
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ABSTRACT
Recombination is a major mechanism that generates variation in populations of the
human immunodeficiency virus type 1 (HIV-1). Mutations that confer replication advantages,
such as drug resistance, often cluster within regions of the HIV-1 genome. To explore how
efficiently HIV-1 can assort markers separated by short distances, we developed a flowcytometry-based system to study recombination. Two HIV-1-based vectors were generated, one
encoding the mouse heat-stable antigen gene and green fluorescent protein gene (GFP), and the
other encoding the mouse Thy-1 gene and GFP. We generated derivatives of both vectors that
contained nonfunctional GFP inactivated by different mutations. Recombination in the region
between the two inactivating mutations during reverse transcription could yield a functional
GFP. Using this system, we determined that the recombination rates of markers separated by
588, 300, 288, and 103 bp in one round of viral replication are 56, 38, 31, and 12%, respectively,
of the theoretical maximum measurable recombination rate. Statistical analyses revealed that at
these intervals, recombination rates and marker distances have a near-linear relationship that is
part of an overall quadratic fit. Additionally, we examined the segregation of three markers
within 600 bp and concluded that HIV-1 recombination does not exhibit high negative
interference. We also examined the effects of target cells and viral accessory proteins on
recombination rate. Similar recombination rates were observed when human primary CD4+ T
cells and a human T cell line were used as target cells. We also found equivalent recombination
rates in the presence or absence of accessory genes vif, vpr, vpu, and nef. These results illustrate
the power of recombination in generating viral population variation and predict the rapid
assortment of mutations in the HIV-1 genome in infected individuals.
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INTRODUCTION
Genetic recombination plays an important role in the evolution of human
immunodeficiency virus type 1 (HIV-1) (34). Recombination shuffles viral genomes and
redistributes the mutations generated from reverse transcription, leading to increased variation
within the infected host and, ultimately, the viral populations distributed throughout the world
(34). Of the more than 70,000 sequences that are catalogued in the HIV sequence database at the
Los Alamos National Laboratory (http://www.hiv.lanl.gov), approximately 8% (> 5,500) are
classified as recombinants. Furthermore, recombinant strains of HIV-1 have been observed
worldwide (13, 16, 25, 27, 37, 45). The inherent ability for HIV-1 to recombine poses a constant
problem for effective anti-HIV-1 treatment because multidrug resistant variants can be generated
by recombining the genome of singly or weakly resistant viruses. The increased variation caused
by recombination also hinders the development of effective vaccines: the induced host immune
response has to combat not only the variants generated by the rapidly changing virus genome but
also all the different subtypes of HIV-1. Therefore, rapid recombination of the HIV-1 genome
creates a vast advantage for the evolution of the virus and an enormous difficulty for the host.
The ability of HIV-1 to carry out frequent recombination is the result of a unique feature
of the retrovirus family: retroviruses package two copies of viral RNA into each virion (15, 22).
During reverse transcription, reverse transcriptase (RT) can use portions of the genomes from
each RNA as templates to generate a recombinant viral DNA (7, 18). Although recombination
can occur in all virions, a genetically different progeny can only be generated from virions with
two different RNAs (heterozygous virions), not from virions with two identical RNAs
(homozygous virions) (17). Heterozygous virions are only generated from cells infected with
more than one retrovirus (double infection) (17). We have previously demonstrated that double
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infection occurs frequently in HIV-1 infection of cultured T cells and primary T cells (8),
providing the basis for the generation of heterozygous virions that allows the observed frequent
recombination.
Frequent HIV-1 recombination has been evident from studies using different approaches.
Studies of individuals infected with more than one genetically distinct HIV-1 revealed that these
patients often also harbor hybrid viruses in their viral populations (13, 16, 25, 27, 37, 45).
Intersubtype recombinants that cause epidemics in certain geographical areas have multiple
break-off points along the genome (34). Additionally, some circulating forms of recombinants
have mosaic genomes that were derived from five or more genetically distinct HIV-1 variants,
emphasizing the common occurrence of double infection and frequent recombination (42). In
addition to the viral populations in infected individuals, recombination events have also been
observed in experimental systems. It has been demonstrated that recombination can occur using
purified RT and nucleic acid templates (5, 10-12, 29); these studies have also yielded interesting
data on different aspects of recombination, such as the effects of the viral nucleocapsid protein
(9, 29, 32, 35, 36) and the templates (5, 11, 12, 32, 35, 36). Using cell-culture-based systems, it
has been demonstrated that HIV-1 recombination is frequent and occurs throughout the viral
genome with potential localized hot spots (6, 19, 21, 23, 24, 46). Comparisons between HIV-1
and the simple retrovirus murine leukemia virus (MLV) revealed that HIV-1 recombines more
frequently than MLV (30, 33).
In a previous study, we measured HIV-1 recombination rates for three genetic distances
(1.9, 1.3, and 1.0 kb) (33). We observed that HIV-1 recombines at exceedingly high rates,
because sequences separated by 1.3 kb segregated as unlinked alleles in a single round of viral
replication. These results also led to questions that could not be easily addressed using the same
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system such as the relationship between recombination rate and marker distances shorter than 1.0
kb. Many of the mutations that cause drug resistance or immune evasion are clustered within 1.0
kb of the viral genome (20, 40). Therefore, it is important to measure how frequently these
mutations can be assorted. Furthermore, because drug selection was used in the previous system
to measure recombination, we could not easily adapt this strategy to measure recombination in
cells that grow in suspension, such as T cells, which are natural target cells for HIV-1.
In this report, we describe the development of a new experimental system that can
measure recombination rates when markers are separated by short distances (0.6 kb or less).
Furthermore, since this system is based on the detection of green fluorescent protein (GFP) and
cell surface proteins that can be labeled with fluorescence antibodies, we can measure the
recombination rates in cultured T cells and primary cells. Using this new system, we have
measured the recombination rates at four genetic distances. In addition, we measured the
frequency of double recombination to test whether HIV-1 recombination exhibits interference.

MATERIALS AND METHODS
Nomenclature and plasmid construction. Plasmids were constructed using standard
molecular cloning techniques (38). The names of all plasmids used in this study begin with “p”,
but the names of the viruses derived from these plasmids do not. Plasmid pHIV-HSA-IRESGFP (a kind gift from Derya Unutmaz, Vanderbilt University) is a pNL4-3-based construct that
encodes gag, pol, tat, and rev but contains inactivating mutations in vif, vpu, vpr, and env.
Additionally, this plasmid has an insertion in the nef reading frame that contains a mouse heatstable antigen gene (HSA) followed by an internal ribosomal entry site (IRES) from
encephalomyocarditis virus and the green fluorescent protein gene (GFP).
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Plasmid pON-fHIG is identical to pHIV-HSA-IRES-GFP, except that an NcoI site in the
plasmid backbone was eliminated by partial NcoI digestion and fill-in reaction with the Klenow
fragment of Escherihia coli DNA polymerase I. Plasmid pON-fTIG was identical to pONfHIG, except that HSA was replaced with the mouse CD90.2 gene, also known as Thy-1. Thy-1
was PCR amplified from pSRalphaLthy (31) (a kind gift from Irvin S.Y. Chen, University of
California at Los Angeles) with primers containing SacII and XhoI sites. The PCR product was
digested with SacII-plus-XhoI and the resulting DNA fragment was inserted into SacII plus XhoI
digested HDV-eGFP (41) to generate pHIV-Thy1. Thy-1 was amplified by PCR from pHIVThy1; the PCR products were digested with NotI plus EcoRI, and inserted into NotI-plus-EcoRIdigested pON-fHIG to generate pfTIG-SL-delta. The sequence between env and the 5’ end of
Thy-1 in pfTIG-SL-delta was replaced with the sequence from pHIV-Thy1 by substituting the
BamHI-BstEII DNA fragment to generate pON-fTIG.
HIV-1 vectors with mutated GFP were constructed by generating PCR products of
mutated GFP, then subcloning the PCR DNA fragment into pON-fHIG or pON-fTIG. Mutated
GFP was generated by single-round or overlapping PCR using pON-fHIG as the template. The
PCR product containing the mutated GFP was digested with NcoI plus XhoI and cloned into
NcoI-plus-XhoI-digested pON-fHIG or pON-fTIG . The names of these plasmids contain a letter
indicating the encoded functional marker (H for HSA and T for Thy-1) and a number indicating
the position of the mutation in GFP from the translational start codon. Plasmid pON-H0, H5,
and H6 contained mutations 15, 500, 603 bp downstream from the translation start codon,
whereas T3 and T6 contained mutations 303 and 603 bp downstream from the GFP start codon,
respectively.
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Helper plasmid pCMV-dGag was derived from pCMV∆8.2 (28) in two steps: first, a 4-bp
frameshift mutation was introduced into the SpeI site in gag to generate pCMV-Spe*. A second
mutation in gag, an in-frame stop codon, was introduced 37 bp downstream of the gag AUG by
site-directed mutagenesis to generate pCMV-dGag.
All constructs were characterized by restriction digestion and the PCR-amplified regions
were verified by DNA sequencing to avoid inadvertent mutations. The phenotypes of the
constructs were characterized by flow cytometry analyses of cells transfected with these
plasmids and cells infected with viruses derived from these plasmids.
Cells, transfections, and infections. The modified human embryonic kidney cell line
293T (14) was maintained in Dulbecco’s modified Eagle’s medium. The human T cell line
Hut/CCR5, derived from Hut78 to express chemokine receptor CCR5 (43), was maintained in
RPMI medium. Media for both cell lines were supplemented with 10% fetal calf serum,
penicillin (50 U/ml), and streptomycin (50 U/ml). Puromycin (1 µg/ml) and G418 (500 µg/ml)
were also added to the medium for Hut/CCR5 cells. All cultured cells were maintained in
humidified 37˚C incubators with 5% CO2.
Primary blood lymphocytes were isolated from healthy donors through HISTOPAQUE
(Sigma) gradients and activated by phytohemagglutinin (2 µg/ml) for 3 days. Activated cells
were maintained in RPMI medium supplemented with 10% fetal calf serum and 200 U/ml
recombinant interleukin-2 for 3-4 days. CD4+ T cells were isolated using the Dynabeads CD4
Positive Isolation Kit, which typically generated > 99% purity of CD4+ T cells as determined by
flow cytometry analyses.
DNA transfections were performed by the calcium phosphate method (38) using an MBS
Mammalian Transfection Kit (Stratagene). Cells were plated at a density of 4 × 106 per 100-
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mm-diameter dish and transfected 18 h later. Viral supernatants were harvested 24 h later,
clarified through a 0.45-µm-pore size filter to remove cellular debris, and used immediately or
stored at -80˚C prior to infection.
For infection of 293T cells, cells were plated in a 100-mm-diameter dish at a density of 1
× 106 cells and infected 18 h later. Serial dilutions were generated from each viral stock and
used for infection in the presence of Polybrene at a final concentration of 50 µg/ml. Viruses
were removed 1 h later, and fresh medium was added to the cells; 48 h postinfection, the cells
were processed and flow cytometry analyses were performed. For infection of Hut/CCR5 cells,
2.5 × 105 or 1 × 106 cells were plated in a 24- or 6-well plate, respectively; infection was
performed without Polybrene, and infected cells were analyzed 72 h postinfection.
Antibody staining and flow cytometry. Cells were stained with phycoerythrin (PE)conjugated α-HSA antibody (Becton Dickinson Biosciences) and allophycocyanin (APC)conjugated α-Thy1 antibody (eBioscience). The concentrations of antibodies used to stain 293T
cells were 0.8 µg/ml (PE-HSA) and 3.6 µg/ml (APC-Thy1.2), whereas the concentrations of
antibodies used to stain Hut/CCR5 cells were 0.48 µg/ml (PE-HSA) and 3.6 µg/ml (APC-Thy-1).
Cells that were used only for flow cytometry analyses were fixed with paraformaldehyde (1%,
final concentration). Flow cytometry analyses were performed on a FACSCalibur (BD
Biosciences), whereas cell sorting was performed on a FACSVantage SE System with the
FACSDiVa Digital Option (BD Biosciences). Data obtained from flow cytometry analyses were
analyzed using FlowJo software (Tree Star).
Calculation of the recombination rate. Multiplicity of infection (MOI) was calculated
as follows. Y represents the number of total analyzed live cells during flow cytometry analyses;
Zi and Zg represent the number of infected cells and the number of GFP+ cells, respectively.
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Infection MOI was calculated as log (1 − Zi/Y) /log ((Y − 1)/Y)/Y, whereas GFP MOI was
calculated as log (1 − Zg/Y) /log ((Y − 1)/Y)/Y. The percent of theoretical maximum
measurable recombination rate for measuring markers 588, 300, 288, and 103 bp apart was
calculated as ((GFP+ MOI / Infection MOI) / 12.5%) × 100%.

RESULTS
Experimental system used to examine HIV-1 recombination. We developed a flowcytometry-based system to measure the recombination rates at marker distances shorter than 1.0
kb in a single round of HIV-1 replication. This system uses three markers: HSA, Thy-1, and
GFP; HSA and Thy-1 are cell-surface proteins that can be detected with specific fluorochromeconjugated antibodies and flow cytometry, whereas GFP is a fluorescent protein. We
constructed two pNL4-3-based HIV-1 vectors, pON-fHIG and pON-fTIG (Fig. 1A). These
vectors contained all the cis-acting elements necessary for virus replication and encoded gag,
pol, tat, and rev. In addition, each vector contained two marker genes in the nef reading frame:
pON-fHIG had HSA and GFP, whereas pON-fTIG had Thy-1 and GFP. HSA and Thy-1 were
expressed by spliced mRNAs, whereas the translation of GFP was facilitated by an IRES from
encephalomyocarditis virus in both vectors.
Three vectors were derived from pON-fHIG by introducing inactivating mutations in
GFP. Plasmid pON-H0 contained 7-nt substitutions between nt 6 and 15 that introduced a stop
codon in each reading frame, with the translation start site as nt 1 (Table 1). Plasmids pON-H5
and pON-H6 contained a +1 frameshift between nt 500 and 501, and between nt 603 and 604 of
GFP, respectively (Table 1). Similarly, two vectors were derived from pON-fTIG: pON-T3 and
pON-T6 contained a +1 frameshift between nt 303 and 304, and between nt 603 and 604 of GFP,
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respectively (Table 1). None of the five plasmids with mutation in GFP gene could express
functional GFP; however, upon recombination, a functional GFP gene could be generated and its
gene products could be scored by flow cytometry. By combining different pairs of vectors, we
could measure the recombination rates for different marker distances.
Experimental procedure used to generate producer cell lines and measure
recombination rates. To measure the recombination rates in a single round of HIV-1
replication, we elected to produce the virus for the recombination assay from established cell
lines containing HIV-1 vector proviruses instead of transiently cotransfecting the two HIV-1
vectors along with helper plasmids into cells. Although more laborious, our procedure
eliminated possible DNA recombination between the two HIV-1 vectors during transfection and
avoided overexpression of transfected plasmids, which would not reflect the true expression of
the integrated proviruses. Furthermore, our procedure allowed us to measure the recombination
events in one complete round of virus replication — from a provirus in the producer cells to a
provirus in the target cells.
The experiments were performed in the following manner (Fig. 1B). First, 293T cells
were transfected with an HIV-1 vector and pHCMV-G (44), a plasmid that expresses vesicular
stomatitis virus G protein that can pseudotype HIV-1. Viral supernatants were harvested,
clarified through a filter, serially diluted, and used to infect fresh 293T cells. A portion of the
infected cells was stained with antibodies and analyzed by flow cytometry. Although this
procedure could easily infect more than 80% of the cells, we selected cell populations that were
infected with an MOI of 0.05 to 0.1 for further experiments. This approach allowed us to avoid
cell populations in which a large proportion of the cells contained more than one virus; selecting
such populations would complicate later analyses (see Discussion). The infected cells were
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enriched by cell sorting (Fig. 1B), and infected by a second virus at an MOI of 0.05 to 0.1; the
doubly infected cells were then sorted until more than 95% of the cells expressed both HSA and
Thy-1. During the generation of the cell lines, cells were sorted no more than a total of four
times. To avoid biases, each cell line consisted of a large number (20,000 to 60,000) of
independently infected cells.
To measure the recombination rate, cell lines expressing both HSA- and Thy-1-encoding
vectors were transfected with helper plasmids, and viruses harvested from these cells were used
to infected the human T cell line Hut/CCR5; the infected cells were then analyzed by flow
cytometry to determine the numbers of cells expressing HSA, Thy-1, or GFP. Two helper
plasmids were used in these experiments: pIIINL(AD8)env, which expressed HIV-1 envelope
from the AD8 strain (8), and pCMV-dGag, which expressed HIV-1 accessory genes vif, vpr,
vpu, tat, rev, and nef. Because 293T cells did not express CD4, virus generated from these cells
could not reinfect the producer cells; additionally, once transferred into Hut/CCR5 cells, the
HIV-1 vectors did not express Env, and thus could not reinfect target cells. Therefore, these
experiments measured recombination events that occurred between the provirus in the producer
cells to the provirus in the target cells — one complete cycle of HIV-1 replication.
Experimental controls for the flow cytometry analyses. Before this new system could
be used for recombination studies, we performed various control experiments to establish the
background of the experimental system and our ability to detect the marker genes. Flow
cytometry analyses were performed on uninfected 293T cells and the producer cells. Uninfected
293T cells stained with anti-HSA and anti-Thy-1 antibodies had negligible numbers of cells that
were positive for any of the three markers (Fig. 2A and B). An example of a producer cell line
doubly infected with ON-H0 and ON-T6 is shown in Fig. 2C and D; although more than 95% of
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the cells were positive for both HSA and Thy-1 expression, none of the cells were positive for
GFP expression (0 in 11,698 live events or less than 0.008%).
To determine the experimental background, we mock-infected Hut/CCR5 cells, stained
these cells with anti-HSA and anti-Thy-1 antibodies, and analyzed them by flow cytometry. An
example is shown in Fig. 2E and 2F; very few cells were positive for HSA, Thy-1, or GFP
expression. Because recombination events were scored by the reconstitution of a functional GFP
gene, we further defined the background of GFP detection. In multiple independent experiments,
we scored a total of more than 2.3 million mock-infected cells and observed 18 GFP+ cells,
indicating a background of ~ 0.0008%. We generated viruses derived from either pON-fHIG or
pON-fTIG, using transient transfection of 293T cells along with helper plasmids, and infected
Hut/CCR5 cells. As shown in the representative analyses (Fig. 2G for ON-fHIG virus infection
and Fig. 2H for ON-fTIG virus infection), most of the cells were either double-negative or
double-positive, indicating equivalent detection of the two marker genes in both HIV-1 vectors.
It was also important that the GFP mutants used in these experiments were indeed
negative for GFP expression; we performed multiple experiments to confirm that all four
mutations in GFP inactivated the gene product (Fig. 2 D and data not shown).
Detection of recombination events for markers separated by 588 bp. Three
independent cell lines doubly infected with ON-H0 and ON-T6 viruses were generated (shown
as cell lines 1, 2, and 3 in Table 2); the GFP mutations in ON-H0 and ON-T6 were 15 and 603
bp downstream of the AUG codon, creating a genetic distance of 588 bp. Helper plasmids were
transfected into producer cell lines, viruses were harvested and used to infect Hut/CCR5 cells,
and the infected cells were analyzed by flow cytometry. Representative mock-infected
Hut/CCR5 cells are shown in Fig. 3A and 3B, and infected Hut/CCR5 cells are shown in Fig. 3C
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and D. As shown in Fig. 3C and D, cell populations that were negative, single-positive, or
double-positive for the markers could be easily detected and scored. Data generated from these
analyses are summarized in Table 2. For example, viruses produced from cell line 1 were used
to infect Hut/CCR5 cells; of the 302,115 live events scored, 132,787 cells expressed at least one
marker (infected cells), and 11,866 cells expressed GFP. To more accurately calculate the
recombination events, we converted the cell numbers into MOI (see Materials and Methods for
formula for conversion); the MOI for infection and GFP+ virus were 0.58 and 0.04, respectively,
indicating that 6.9% of the infection events generated GFP+ phenotypes.
Calculation of theoretical maximum GFP+ phenotype. In this experimental system,
we could measure the virus titers of the two parental phenotypes and the GFP+ recombinant
phenotype. Assuming that RNA expression of the two parental vectors was equal in the
producer cell and that RNA packaging was random, 50% of the virion produced would contain a
copy of RNA from each parent (heterozygotes), 25% would contain two copies of RNA from
one parent, and 25% would contain RNAs from the other parent (both homozygotes). The GFP+
phenotype could only be generated from reverse transcription of the heterozygous virions. With
two mutations in GFP, four GFP genotypes could be generated during recombination (Fig. 4); of
these, only the GFP without any mutation could express functional proteins. At the maximum
recombination rate, the two markers in GFP assorted randomly; of all the virions generated from
the producer cells, only 12.5% of the progeny was expected to reconstitute a functional GFP.
Therefore, at most, 12.5% of the infection events should yield the GFP+ phenotype. When we
observed that 6.9% of the infection events had the GFP+ phenotype, recombination between
these two markers in GFP separated by 588 bp occurred at 55.4% of the theoretical maximum
measurable rate (6.9%/12.5% × 100%) (Table 2).
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Recombination rates for markers separated by 300, 288, and 103 bp. We generated
cell lines containing both ON-H0 and ON-T3 proviruses, and cell lines containing both ON-T3
and ON-H6 proviruses. The distance between the H0 and T3 mutations in GFP was 288 bp,
whereas the distance between the T3 and H6 mutations was 300 bp. Despite the similar genetic
distance between these two sets of mutations, they contained completely different nucleotide
sequences: H0 to T3 comprised the sequences from the 5′ portion of GFP whereas T3 to H6
encompassed the 3′ portion of GFP (Fig. 1). We measured the frequencies at which GFP+
phenotypes were generated among infection events in cell lines containing either set of
mutations; these results are summarized in Table 3 and 4. The recombination rate between H0
and T3 (288 bp) was 30.7% ± 4.3% standard deviation (SD) of the theoretical maximum
measurable rate; the recombination rate between T3 and H6 (300 bp) was 38.2% ± 5.6 % (SD).
There were overlaps among the three sets of measurements of the two distances, indicating that
the two measured sequences yielded similar recombination rates.
We also generated cell lines containing ON-H5 and ON-T6 proviruses and measured the
recombination rate when the two markers were separated by 103 bp. The data generated from
three independent experiments indicated that 1.4 % of the infection events were GFP+, or 11.5%
± 2.4 % (SD) of the theoretical maximum measurable recombination rate.
Effect of accessory genes on the recombination rate. The recombination experiments
described above were performed in the presence of the accessory gene products. It has been
shown that some accessory genes could affect the HIV-1 mutation rate or the process of reverse
transcription (1, 26, 39). To examine the effect of accessory genes on the recombination rate, we
also performed parallel experiments without the expression of vif, vpr, vpu, and nef by omitting
the helper construct pCMVdGag. Results from these experiments are summarized in Tables 2, 3,
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4, and 5; these results indicated that although the presence of the accessory gene products might
have affected the infectivity of the virus as previously described, these gene products did not
affect the overall recombination rate significantly (two-way ANOVA, P = 0.435; analysis of
covariance, P = 0.514) (Fig. 5).
HIV-1 recombination in primary CD4+ activated T cells. We also measured the HIV1 recombination rate in activated human primary CD4+ T cells. In order to make direct
comparisons between the recombination rates in different target cells, we performed infection of
the primary cells with the same virus stocks that were used to generate data for Tables 2, 4, and
5. Only viruses propagated in the presence of all accessory genes were used in these
experiments. Three days postinfection, these cells were processed and analyzed by flow
cytometry. For each recombination rate, we performed experiments using cells derived from
three different donors and viruses generated from three independent cell lines. The ratio of GFP
MOI/infection MOI for markers separated by 588, 288, and 103 bp were 7.1% ± 1.1 % (SD),
4.7% ± 0.5% (SD), and 2.0% ± 0.3% (SD), respectively. These data correspond to 56.8, 37.6,
and 16% of the theoretical maximum measurable recombination rate, which were similar to those
determined in Hut/CCR5 cells (Fig. 5).
Assortment of the HSA, Thy-1, and GFP markers in target cells. The two parental
vectors used in this study had different marker genes upstream of GFP. Therefore, we could also
analyze the distribution of the GFP+ cells in HSA+ and Thy-1+ cells to monitor additional
recombination events. The distance between the 3′ end of HSA/Thy-1 to the H0, T3, and H5
mutations in GFP were 0.6, 0.9, and 1.1 kb, respectively. In order for the GFP+ provirus in the
H0-T6 or H0-T3 experiment to have HSA, RT would have to switch templates between the 0.6
kb separating the HSA and the first 4 nt of GFP on the Thy-1-containing RNA. Similarly, in
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order for the GFP+ provirus to have Thy-1 or HSA in the T3-H6 or the H5-T6 experiments, RT
would have to switch templates within 0.9 or 1.1 kb, respectively. We also analyzed the
distribution of GFP+ cells in HSA+ and Thy-1+ cells (Fig. 6). In both the H0-T6 and H0-T3
experiments, the ratios of GFP+ in HSA+ cells were higher than those of GFP+ in Thy-1+ cells,
whereas in T3-H6 and H5-T6 experiments, the ratios of GFP+ in HSA+ cells were similar to
those of GFP+ in Thy-1+ cells. The marker distributions in these experiments were similar to the
expected distribution based on the distance. For example, we expected that more GFP+ viruses
would have Thy-1 markers in the H0-T6 experiment because the recombination rate was under
the maximum rate when markers were separated by 0.6 kb. These data suggested that HIV-1
recombination does not have high negative interference, in contrast to the previous proposal by
others (46). Although able to provide useful information, the distribution of the markers could
be complicated by the doubly infected cell population and the expression of the two parental
viruses. We performed further experiment to address whether HIV-1 recombination has high
negative interference.
Generating GFP+ phenotype by double-crossover events. High negative interference
is defined by double recombination generated at a frequency far higher than predicted from the
rate of the single recombination. To directly test whether HIV-1 recombination exhibits high
negative interference, we generated pON-H06 (Fig. 1A), which is identical to pON-H0 except it
also has the H6 mutation in GFP. Using the same protocol described in Fig. 1B, we generated
two cell lines doubly infected with ON-H06 and ON-T3, and measured the rates at which GFP+
viruses were generated after one round of HIV-1 replication in the presence or absence of the
accessory genes. These results are summarized in Table 6. Based on our data from the H0-T3
and T3-H6 experiments, we could calculate the theoretical frequency at which GFP+ viruses
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would be generated if the recombination events were independent. In the H0-T3 and T3-H6
experiments, the ratio of the GFP+ phenotype in the total infection events was 3.8 and 5.1%,
respectively. Because heterozygous viruses were present in only half of the viruses, and only
half of the recombinant genotypes could be scored in this system, the recombination rate
between H0-T3 and T3-H6 was 15.2% (3.8% × 2 × 2) and 20.4% (5.1% × 2 × 2), respectively.
Therefore the predicted double recombination rate was 3.1% (15.2% × 20.4%). Given the
inability to score one of the double-crossover recombinant genotypes and the presence of the
homozygous viruses, the expected ratio of the GFP+ phenotype in infected events was 0.77%
(3.1% / 4). The predicted numbers based on single recombination rates are very similar to our
observed rate: the average ratio of GFP+ in infected events was 0.93%. Therefore, our data do
not support the hypothesis that HIV-1 recombination exhibits high negative interference.

DISCUSSION
Development of a versatile system for HIV-1 recombination studies. In this report,
we describe the development of a system to examine factors that influence the HIV-1
recombination rate. Detection of the infected cells and recombinants is based on the expression
of proteins that can be scored by flow cytometry. The advantages of this system are the ability to
detect recombination events in T cells and primary cells, and the ease and speed of collecting
data from samples with large numbers of cells. Additionally, our system is versatile; we can
directly measure recombination rates at various distances up to 600 bp using the mutants with
defined genotypes and phenotypes to generate recombinants. Furthermore, we collected viruses
used in recombination studies from infected, sorted producer cells, thereby eliminating
background problems such as the detection of DNA recombination events of the transfected
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parental vectors and allowing us to measure events that occur at lower frequencies. Recently,
another flow-cytometry-based assay for studying HIV-1 recombination was described, which
uses derivatives of GFP that fluoresce at different wavelengths as markers and reconstitution of
GFP* as a mean to measure recombination (24). Although based on similar principles, the
system is limited to mutations that conferred alteration of the fluorescence wavelength, and could
be complicated by the presence of more than one mutation that could affect the protein excitation
wavelength and the multiple recombinant genotypes that could have varied phenotypes.
Calculation of HIV-1 recombination rate. Previously, we measured the recombination
rates of spleen necrosis virus (SNV), MLV, and HIV-1 (2, 17, 33). In these studies, we used two
parental vectors each encoding a functional and a nonfunctional drug-resistance gene;
recombination events were scored by the generation of recombinants with two functional drugresistance genes. In these previous experiments, three drug-selection regimens — two single
and one double —were used to measure the titers of the two parents and the recombinant,
respectively. The recombination rate was calculated by dividing the double-drug-resistance titer
with the lower of the two parental titers; the resulting number was then doubled to account for
the recombinant with two nonfunctional genes, which could not be detected.
In our current system, flow cytometry analyses can simultaneously measure the
expression of all three markers. Therefore, in addition to measuring the cell population infected
by viruses with the parental phenotypes, and by virus with the recombinant phenotype (GFP+),
we can directly determine the total infected cell population. Based on Poisson distribution, the
number of infected cells is not always in linear proportion to the number of infection events,
especially at higher MOIs. Additionally, the number of GFP+ cells is always lower than the total
number of infected cells. Therefore, to estimate the recombination rate more accurately, we
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converted the numbers of infected cells to MOIs prior to calculation. This concern is less of an
issue for previous studies because the numbers of drug resistance colonies are always counted on
cells infected with virus at low MOIs.
To better appreciate that the true frequency with which markers separated by a given
distance segregate in one round of viral replication, we compared the rate at which GFP+ was
generated during infection to the theoretical maximum measurable recombination rate. We
calculated the theoretical maximum measurable recombination rate in this experimental design
(Fig. 4) based on the assumption that the two parents had the same level of RNA expression. In
all our experiments, the expression of the HSA and Thy-1 indicated that the titers of the two
parental viruses were similar, generally within two-fold of each other. Because all the producer
cells were pools of infected cells, it was possible that the two parents were expressed at very
different levels in each cell, yet generated similar titers when viruses were harvested from a large
pool of cells. To reduce this bias, we infected the cells with low MOIs (0.1 to 0.05) during the
generation of our cell lines to decrease the probability of the presence of multiple proviruses
from the same parent in one cell. Therefore, the 12.5% of GFP+ cells estimated (Fig. 4) is likely
to reflect the maximum that can be observed in our experimental condition. On the other hand, if
we convert the two fold difference in the parental titer in some experiments to differences of
RNA expression in the producer cells, the theoretical maximum measurable recombination rate
would be 11.1%, similar to the 12.5% we estimated in Fig. 4.
Near-linear relationship between recombination rate and marker distance at the
range of 0.1 to 0.6 kb that is part of an overall quadratic fit. The recombination rates
measured in this study are shown in Fig. 7A. We performed statistical analyses on the
recombination rates measured at the aforementioned four distances. We found that distance is a
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significant factor that affects recombination rates (two-way ANOVA, P < 0.001; analysis of
covariance, P < 0.001). Further analyses indicated that at this range, the relationship between
recombination rate and marker distance is near-linear and fits a regression model involving both
a linear component (first power of distance) and a quadratic component (second power of
distance), with both components being significant (P < 0.001 for the linear and P = 0.015 for the
quadratic component) and an R2 value of 0.985.
To gain insight into the overall relationship between recombination rate and marker
distance, we also converted our previous measurements of recombination rates at 1.0, 1.3, and
1.9 kb into theoretical maximum measurable recombination rates. We then added these rates to
the rates determined in this report and generated a model to fit these data (with the caveat that the
data came from two different studies). The resulting model illustrates that the relationship
between recombination rate and marker distance has a quadratic fit with the linear and quadratic
components being the first and second powers, respectively (Fig. 7B). This model has an
outstanding fit to the data, with a R2 value of 0.984; of the 41 data points from the experiments,
only one point was outside the 95% confidence level of the model.
We also generated a simple simulation to predict the relationship between marker
distance and recombination rate. This simulation has the following assumptions: the frequency
of crossover between two markers is directly proportion to the distance, and the crossover events
are independent, occur randomly throughout the distance, and have a Poisson distribution.
Furthermore, we took into the account that between the two markers, only odd numbers of
crossover events will generate a recombinant genotype whereas even numbers of crossovers will
not. The stimulation is shown in Fig. 7C and resembles the graph shown in Fig. 7B. Therefore,
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our data are consistent with the hypothesis that the frequency of crossover events are
proportional to the distance between the markers and are independent from one another.
Lack of interference in HIV-1 recombination. Adding to the evidence in our proposal
that crossover events in HIV-1 are independent is our observed lack of interference in the
generation of a double recombinant. Previously, it was hypothesized that HIV-1 recombination
exhibits high negative interference (46). This hypothesis was based on the mapping data of the
crossover events in the HIV-1 genomes, in which some had multiple crossovers while others did
not have any crossovers. It is possible that in the previous study, the viral genomes that did not
have crossovers came from homozygous viruses. Alternatively, although unlikely, we cannot
exclude the possibility that recombination does not exhibit high negative interference in GFP but
exhibit interference in the HIV-1 genome sequences. Our previous studies indicated that
recombination in SNV and MLV exhibit high negative interference (3, 4). We are currently
dissecting the mechanisms that cause high negative interference in SNV and MLV but not in
HIV-1.
Implications of the high recombination frequency. One of the major hindrances in the
treatment of HIV-1 infection is viral variation. The high rate of HIV-1 recombination
contributes to viral variation, which hinders effective treatments. Through recombination,
multidrug-resistant variants can be generated quickly in a host; for example, sequences separated
by 100 bp can be assorted at a frequency of 11% per replication cycle, and double-crossover
events occur frequently without interference. With the high rates of HIV-1 replication in
infected individuals, recombination can assort the genome in a short period of time. The ability
of HIV-1 to evolve presents a daunting challenge for HIV-1 treatment and vaccine development.
However, if we can further define and understand the pathways that HIV-1 uses to generate
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variation, we can better estimate the evolutionary potential and limitations of HIV-1. This
understanding can help us design better therapeutic strategies for the treatment of HIV-1
infection. To continue building the scaffold needed to understand the evolution potential of
HIV-1, we are currently performing further studies to elucidate the mechanisms and factors
important for recombination.
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TABLE 1. Sequence comparison between wild-type and mutant GFP

Mutation

DNA sequence in GFP*

H0
Wild-type

ATGGTGAGCAAGGGCGAG

Mutant

ATGGTAGTTAACTGAGAG

Wild-type

CATCTTCTTC-AAGGACGACG

Mutant

CATCTTCTTCGAAGGACGACG

T3

H5
Wild-type

TGAACTTCAA-GATCCGCCAC

Mutant

TGAACTTCAAGGATCCGCCAC

Wild-type

ACAACCACTAC-CTGAGCACC

Mutant

ACAACCACTAGTCTGAGCACC

H6/T6

* Bold letters denote substituted and inserted nucleotides.
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TABLE 2. Recombination between two markers separated by 588 bp.
Total

Infected

GFP+

Infection

GFP

GFP MOI /

% of

live events

cells

cells

MOI

MOI

Infection MOI

TMMRR*

With all accessory gene products
Cell line 1

302,115

132,787

11,866

0.58

0.040

0.069

55.4%

Cell line 2

311,294

108,238

7,896

0.43

0.026

0.060

48.1%

Cell line 3

134,998

53,493

5,366

0.50

0.041

0.080

64.3%

Mean ± SD

55.9% ± 8.1%

Without Vif, Vpr, Vpu, and Nef
Cell line 1

244,153

92,266

7,543

0.47

0.031

0.066

52.9%

Cell line 2

323,309

102,981

7,682

0.38

0.024

0.063

50.2%

Cell line 3

153,351

44,530

3,800

0.34

0.025

0.073

58.5%

Mean ± SD

53.9% ± 4.3%

* TMMRR: Theoretical maximum measurable recombination rate.

115

TABLE 3. Recombination between two markers separated by 300 bp.
Total

Infected

GFP+

Infection

GFP

GFP MOI /

% of

live events

cells

cells

MOI

MOI

Infection MOI

TMMRR*

With all accessory gene products
Cell line 1

169,742

68,118

4,751

0.51

0.028

0.055

44.3%

Cell line 2

457,070

125,496

6,071

0.32

0.013

0.042

33.3%

Cell line 3

377,710

142,939

8,228

0.48

0.022

0.046

37.1%

Mean ± SD

38.2% ± 5.6%

Without Vif, Vpr, Vpu, and Nef
Cell line 1

177,088

43,332

2,513

0.28

0.014

0.051

40.7%

Cell line 2

543,741

133,692

6,768

0.28

0.013

0.044

35.5%

Cell line 3

710,696

157,916

7,463

0.25

0.011

0.042

33.6%

Mean ± SD

36.6% ± 3.7%

* TMMRR: Theoretical maximum measurable recombination rate.
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TABLE 4. Recombination between two markers separated by 288 bp.
Total

Infected

GFP+

Infection

GFP

GFP MOI /

% of

live events

cells

cells

MOI

MOI

Infection MOI

TMMRR

With all accessory gene products
Cell line 1

174,404

72,866

4,140

0.54

0.024

0.044

35.5%

Cell line 2

540,508

195,323

8,225

0.45

0.015

0.034

27.4%

Cell line 3

271,641

127,694

6,218

0.64

0.023

0.036

29.2%

Mean ± SD

30.7% ± 4.3%

Without Vif, Vpr, Vpu, and Nef
Cell line 1

176,526

41,014

1,777

0.26

0.010

0.038

30.6%

Cell line 2

469,566

144,843

6,371

0.37

0.014

0.037

29.6%

Cell line 3

585,638

203,767

8,356

0.43

0.014

0.034

26.9%

Mean ± SD

29.0% ± 1.9%
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TABLE 5. Recombination between two markers separated by 103 bp.
Total

Infected

GFP+

Infection

GFP

GFP MOI /

% of

live events

cells

cells

MOI

MOI

Infection MOI

TMMRR

With all accessory gene products
Cell line 1

155,972

63,480

1455

0.52

0.009

0.018

14.3%

Cell line 2

1,067,637

405,475

6,241

0.48

0.006

0.012

9.8%

Cell line 3

1,049,218

321,544

5,021

0.37

0.005

0.013

10.5%

Mean ± SD

11.6% ± 2.4%

Without Vif, Vpr, Vpu, and Nef
Cell line 1

171,884

44,695

841

0.30

0.005

0.016

13.0%

Cell line 2

1,094,731

387,098

5,960

0.44

0.005

0.013

10.0%

Cell line 3

1,319,480

372,408

5,565

0.33

0.004

0.013

10.2%

Mean ± SD

11.1% ± 1.7%

* TMMRR: Theoretical maximum measurable recombination rate.
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TABLE 6. Recombination between three markers using ON-H06 and ON-T3 viruses.
Total

Infected

GFP+

Infection

GFP

GFP MOI /

live events

cells

cells

MOI

MOI

Infection MOI

With all accessory gene products
Cell line 1

919,357

223,561

2,379

0.28

0.003

0.0093

Cell line 2

1,034,680

343,027

3,868

0.40

0.004

0.0093

Without Vif, Vpr, Vpu, and Nef
Cell line 1

930,100

262,201

2,946

0.33

0.003

0.0096

Cell line 2

813,916

326,331

3,955

0.51

0.005

0.0095
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FIGURE LEGENDS

FIG. 1. Viral vectors and protocol used to measure HIV-1 recombination rates. (A)
General structures of the vectors. All listed vectors have similar structures but differ in the
encoded marker genes. Asterisk, inactivating mutation in GFP. (B) Protocol used to measure
the recombination rates of HIV-1.

FIG. 2. Representative flow cytometry analyses of mock-infected cells, producer cells,
and cells infected with control plasmids. (A and B) Analyses of mock-infected 293T cells
stained with anti-HSA and anti-Thy-1 antibodies. (C and D) Analyses of a producer cell line
used for virus production. This cell line was sequentially infected with ON-H0 and ON-T3 at
low MOIs; HSA+ and Thy-1+ cells were enriched by sorting, stained with antibodies, and
analyzed. (E and F) Analyses of uninfected Hut/CCR5 target cells stained with anti-HSA and
anti-Thy-1 antibodies. (G) Analysis of Hut/CCR5 target cells infected with ON-fHIG virus and
stained with anti-HSA antibody. (H) Analysis of Hut/CCR5 cells infected with ON-fTIG virus
and stained with anti-Thy-1 antibody. In all panels, the x- and y-axes denote the expression of a
particular marker as indicated.

FIG. 3. Representative flow cytometry analyses of mock-infected and infected target
cells. (A and B) Analyses of mock-infected Hut/CCR5 target cells stained with anti-HSA and
anti-Thy-1 antibodies. (C and D) Analyses of Hut/CCR5 target cells infected with virus
harvested from a producer cell line harboring both ON-H0 and ON-T6.
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FIG. 4. Distribution of GFP genotypes and phenotypes in the progeny generated from
doubly infected cells after one round of viral replication. Vectors ON-H0 and ON-T6 were used
as examples (shown as H0 and T6, respectively). Several assumptions were made in the
calculated frequency. First, the 25%: 50%: 25% distribution of the virion content was based on
the assumptions that H0 and T6 were expressed at similar levels in the producer cells and virion
RNAs were packaged randomly. Second, the 12.5% distribution of each genotype was based on
the assumption that H0 and T6 markers segregated as unlinked markers. GFP−, cells that did not
express functional GFP; GFP+, cells expressing functional GFP.

FIG. 5. Effects of accessory proteins and target cells on HIV-1 recombination. The yaxis represents the percentage of the theoretical maximum measurable recombination rate
(TMMRR); x-axis, distances between markers. White and gray bars represent the average
recombination rates measured in the presence or absence, respectively, of accessory genes vif,
vpr, vpu, and nef in the experimental system using Hut/CCR5 as target cells. Black bars
represent the recombination rate in the presence of accessory genes using activated primary T
cells as the target cells. All of the histograms show the average of three independent
experiments; standard deviations are shown as error bars.

FIG. 6. Distribution of the GFP+ phenotype in HSA+ and Thy-1+ cells. The y-axis
denotes the percentage of GFP+ cells; x-axis, vector pairs used. White bars represent GFP+ cells
within the HSA+ populations; black bars, GFP+ cells within the Thy-1+ populations.
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FIG. 7. Relationship between HIV-1 recombination rate and marker distance. (A) Nearlinear relationship between recombination rate and marker distance in the 0.1 to 0.6 kb range.
(B) The relationship between HIV-1 recombination rate and marker distances has a quadratic fit.
All data points are shown as triangles, the quadratic fit is shown as a black line, and the 95%
confidence level is shown as dotted lines. (C) Simulation of observed recombination rate. This
simulation is based on the assumptions that the frequency of crossover event is proportional to
the marker distance, crossover occurs randomly throughout the genome, and crossovers are
independent events. The x-axis, marker distance; y-axis, percentage of theoretical maximum
measurable recombination rate (TMMRR).
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Discussion
The general theme of this dissertation is retroviral evolution. The ability of HIV1 to evolve poses the greatest threat to developing an effective therapy to fighting the
AIDS pandemic. The ability to generate variation and the relative plasticity of the viral
genome to tolerate variation allows HIV-1 to quickly develop drug resistance mutations
and hinder the development of vaccines. The high mutation rate of HIV-1 and high viral
loads found in patients contribute greatly to the evolution of HIV-1. Because of these
phenomena, experiments were set forth in this thesis to study retroviral evolution, albeit
through a simple retrovirus. Another major mechanism for retroviruses to generate
variation is recombination. Through work in this thesis, I discovered that HIV-1 exhibits
a extremely high recombinogenic nature, which underscores the need to develop
therapies that fight recombination.
The first chapter introduced the significance of studying retroviruses, the
retroviral lifecycle, and selected literature known concerning evolution and retroviral
recombination. This chapter provided the necessary background information to
understand the experiments and concepts set forth in the work presented in this thesis. In
the second chapter, I described a project that was designed to study the evolution of a
defective simple retrovirus. The goal of this project was to gain a greater understanding
of evolution dynamics and identify important sequences and/or residues important to the
replicating retrovirus. In the third chapter, I discussed HIV-1 recombination and
described the project that measures the recombination rate of HIV-1 at three genetic
marker distances. Within the fourth chapter, I presented the project that resulted in the
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development of a novel system to measure HIV-1 recombination and measured the
recombination rate at exceedingly short genetic marker distances.
Allowing defective viruses to evolve in tissue culture has proven to be a fruitful
strategy in some instances (3, 11, 23). However, a defective hybrid simple retrovirus that
replicated at a 100-fold reduction over wild type evidently had too much deficiency to
evolve in a timely manner in our experiment. Following the initial burst of virus after
transient transfection, replication was not detected in the 239T cell line. Using two
different approaches, we could not detect virus replication, even after fifty-six days in
tissue culture. Since viral replication provides the opportunity for a virus population to
mutate and adapt, the lack of replication hinders the further development of the project.
A cell line that encourages greater viral replication should provide the material needed to
move this project forward.
Because of two conflicting reports (7, 12), it was unknown whether SNV could
replicate in human cells. We demonstrated that 293T cells could be infected by and
could produce SNV virus. This knowledge could be valuable to the field of gene therapy.
Retroviral vectors are one tool used for those scientists pursuing gene therapy as a
strategy to fight disease. SNV can replicate in human cells, although with less efficiency
than other viruses, such as MLV. Although we discovered that SNV could replicate
within human cells in 2000, recently published papers have confirmed these results (18,
19).
From the first report (4), there have been several studies focusing on HIV-1
recombination (9, 10, 13, 14, 17, 25). Most of these experiments gave valuable
information about the subject, but none of them provided a quantitative measurement of
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the recombination rate and related it to genetic marker distances in one round of
replication. In the third chapter, I described our experiments that measured
recombination rates when markers are separated by a distance of 1.0 kb and greater. The
recombination rate reached the maximum rate at 1.3 kb; therefore, markers that are
separated by 1.3 kb or more segregate as unlinked alleles. This is an astonishingly high
recombination rate considering that MLV and SNV recombine at rates of 6- to 10-fold
less at the same distances (1, 2, 8). When the recombination rate for HIV-1 was
measured with markers 1.0 kb apart, it was 84% of the theoretical maximum measurable
recombination rate. These results suggest that where markers are separated at distances
1.3 kb apart and above illustrate a definite plateau, the distance of 1.0 kb might prove to
be the point of transition where the recombination rate becomes proportional to genetic
marker distance. Based on the marker distances versus recombination rate profile of
MLV (1), it is logical to assume that a linear relationship exist for HIV-1. However, it
could not be determined by the experiments performed in chapter three.
Several conclusions are reached from this work. First, full-length RNA
transcripts from two proviruses in a dually infected cell can be assorted in a random
manner; that is, heterozygotic virion can be generated at the maximum rate, which is 50%
of the total virion population. Second, template-switching events occur at a high
frequency. Based on the measured rates, most, if not all, DNA molecules generated
through HIV-1 reverse transcription contain genetic information from portions of two copackaged RNAs. Third, two drug resistance mutations located at different positions in
the viral genes of two different proviruses in dually infected cells will produce progeny
containing both mutations. This work, along with other recombination studies (9, 10, 13,
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14, 17, 25), indicates that HIV-1 recombination is a major mechanism for generating
variation within the viral genome.
In the fourth chapter, I described further studies on HIV-1 recombination. We
determined the recombination rate for HIV-1 when markers were separated by less than
0.6 kb. To perform this study, we developed a new flow cytometry-based system to
study HIV-1 recombination. The system used for recombination studies described in
chapter 3 was based on reconstitution of two functional drug resistance genes separated
by IRES, which is 0.6 kb in length. This system yielded several disadvantages. First, we
could not easily adapt the system to measure recombination rates when markers were
separated by less than 1.0 kb. Second, because drug selection and the number of double
drug resistant colonies were used to calculate recombination, this system could not be
adapted to measure the recombination rate in cells that grow in suspension, such as T
cells, the natural host cells for HIV-1. Third, the previous assay proved to be very time
consuming. A new, flow cytometry-based assay can bypass these disadvantages.
Using the new system, we have measured the recombination rate of HIV-1 when
markers were between 0.1 and 0.6 kb apart. We observed a near linear relationship
between marker distance and the recombination rate. The recombination rate for 0.10,
0.29, 0.30, 0.59 kb was 11.6, 30.7, 38.2, and 55.9% of the theoretical maximum
measurable recombination rate. We have also examined whether the presence or absence
of accessory proteins vif, vpr, vpu, and nef had an effect on the recombination rate.
Recombination rates for the aforementioned distances do not change significantly with or
without vif, vpr, vpu, and nef. The effect of target cells also did not alter the
recombination rate. The above experiments were performed with the Hut/CCR5 cell line
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as target cells. When we used primary CD4+ T lymphocytes, as target cells, the
recombination rates were not significant different compared with Hut/CCR5 cells.
Recombination in some retroviruses, such as MLV and SNV, exhibit high
negative interference (2, 8), which is defined by multiple cross-over events occurring
more frequently than expected when calculated from single recombination events. This
means that once a recombination event occurs, the chances are greater for a second event.
Experiments described in chapter four determined that HIV-1 recombination does not
exhibit high negative interference. HIV-1 recombination differs from MLV in at least
two aspects: one, HIV-1 recombines at a rate substantially higher than MLV, and two,
HIV-1 recombination does not exhibit high negative interference.
The development of a novel flow cytometry-based system based on to study HIV1 recombination increases the speed at which new studies can be performed. Our
previous system using drug resistance genes as markers took considerable time to
perform. For example, once the required vectors were generated, it would take more than
3 months to acquire the cell lines and obtain the recombination rate. With the flow
cytometry method, the time required for each experiment can be reduced significantly. In
addition, testing multiple hypotheses in parallel is more rapid and feasible.
Several conclusions can be made from the work described in chapter three and
chapter four. As stated previously, recombination is a major determinant of variation in
HIV-1. Since, during HIV-1 replication, the vast majority of the heterozygotic virions
can be generated efficiently and recombination can occur frequently. Therefore, any
dually infected cell with similar proviruses should produce recombinant progeny. This is
consistent with sequence analyses on circulating recombinant forms from infected
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patients (20). Several of these circulating recombinant forms are hybrid virus, some of
which contain sequences from up to five different genetically distinct ancestries (22).
Sequence analyses of HIV-1 variants from dually infected individuals frequently recover
recombinants (5, 6, 15, 16, 21, 24). We demonstrated that even at a short genetic
distance, such as 100 bp, frequent recombination can occur. Among the three cell types
that were used, namely 293T cells in chapter three and Hut/CCR5 and primary T
lymphocytes in chapter four, there did not seem to be an appreciable difference in
recombination. Although this does not rule out the possibility that recombination could
be more frequent in other untested cell types, it shows that an established immortalized
cell line such as Hut/CCR5 can give biological relevant data.
In summary, this thesis focused on retroviral evolution and recombination. First,
the evolution of a defective simple retrovirus was studied. Although this project failed to
yield better-fit viruses, it demonstrated the importance of viral replication capacity on
viral evolution and adaptation. Second, HIV-1 recombination projects focused on
determining the frequencies of HIV-1 recombination in one round of viral replication at
multiple marker distances and factors that affect the recombination rate. Furthermore,
these studies defined the relationship between the recombination rate and marker
distances. The results and conclusions in this thesis provide the scientific community a
more comprehensive understanding on the role HIV-1 recombination plays in variation
and how recombination must be considered in order to develop effective drugs and/or
vaccines.
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